AU2002214034A1 - Radiopharmaceuticals for diagnosing alzheimer's disease - Google Patents
Radiopharmaceuticals for diagnosing alzheimer's diseaseInfo
- Publication number
- AU2002214034A1 AU2002214034A1 AU2002214034A AU2002214034A AU2002214034A1 AU 2002214034 A1 AU2002214034 A1 AU 2002214034A1 AU 2002214034 A AU2002214034 A AU 2002214034A AU 2002214034 A AU2002214034 A AU 2002214034A AU 2002214034 A1 AU2002214034 A1 AU 2002214034A1
- Authority
- AU
- Australia
- Prior art keywords
- compound
- chloro
- formula
- oxoethoxy
- benzyl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 208000024827 Alzheimer disease Diseases 0.000 title claims description 54
- 239000012217 radiopharmaceutical Substances 0.000 title claims description 7
- 229940121896 radiopharmaceutical Drugs 0.000 title claims description 7
- 230000002799 radiopharmaceutical effect Effects 0.000 title claims description 7
- 150000001875 compounds Chemical class 0.000 claims description 115
- -1 monoalkylamino Chemical group 0.000 claims description 72
- 102100031172 C-C chemokine receptor type 1 Human genes 0.000 claims description 62
- 101710149814 C-C chemokine receptor type 1 Proteins 0.000 claims description 62
- 150000003839 salts Chemical class 0.000 claims description 26
- 238000000034 method Methods 0.000 claims description 24
- 239000001257 hydrogen Substances 0.000 claims description 19
- 229910052739 hydrogen Inorganic materials 0.000 claims description 19
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims description 19
- 125000000217 alkyl group Chemical group 0.000 claims description 15
- 239000002738 chelating agent Substances 0.000 claims description 13
- 230000002285 radioactive effect Effects 0.000 claims description 13
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims description 12
- 238000006243 chemical reaction Methods 0.000 claims description 10
- 125000005843 halogen group Chemical group 0.000 claims description 10
- 125000004432 carbon atom Chemical group C* 0.000 claims description 9
- 230000008499 blood brain barrier function Effects 0.000 claims description 8
- 210000001218 blood-brain barrier Anatomy 0.000 claims description 8
- 238000003745 diagnosis Methods 0.000 claims description 7
- 125000005647 linker group Chemical group 0.000 claims description 6
- 230000008569 process Effects 0.000 claims description 6
- 229920006395 saturated elastomer Polymers 0.000 claims description 6
- 125000003118 aryl group Chemical group 0.000 claims description 5
- 125000004429 atom Chemical group 0.000 claims description 5
- 125000004663 dialkyl amino group Chemical group 0.000 claims description 5
- 230000027455 binding Effects 0.000 claims description 4
- 238000002600 positron emission tomography Methods 0.000 claims description 4
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims description 4
- CIUQDSCDWFSTQR-UHFFFAOYSA-N [C]1=CC=CC=C1 Chemical group [C]1=CC=CC=C1 CIUQDSCDWFSTQR-UHFFFAOYSA-N 0.000 claims description 3
- 125000005091 alkenylcarbonylamino group Chemical group 0.000 claims description 3
- 125000004702 alkoxy alkyl carbonyl group Chemical group 0.000 claims description 3
- 125000003806 alkyl carbonyl amino group Chemical group 0.000 claims description 3
- 125000004658 aryl carbonyl amino group Chemical group 0.000 claims description 3
- 125000001951 carbamoylamino group Chemical group C(N)(=O)N* 0.000 claims description 3
- 125000005221 halo alkyl carbonyl amino group Chemical group 0.000 claims description 3
- 125000000623 heterocyclic group Chemical group 0.000 claims description 3
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims description 3
- 238000004519 manufacturing process Methods 0.000 claims description 3
- 125000004433 nitrogen atom Chemical group N* 0.000 claims description 3
- 125000004430 oxygen atom Chemical group O* 0.000 claims description 3
- 125000004434 sulfur atom Chemical group 0.000 claims description 3
- 125000003917 carbamoyl group Chemical group [H]N([H])C(*)=O 0.000 claims description 2
- 239000003638 chemical reducing agent Substances 0.000 claims description 2
- 125000001309 chloro group Chemical group Cl* 0.000 claims description 2
- 229910052751 metal Inorganic materials 0.000 claims description 2
- 239000002184 metal Substances 0.000 claims description 2
- XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 description 56
- 239000000243 solution Substances 0.000 description 51
- DLFVBJFMPXGRIB-UHFFFAOYSA-N Acetamide Chemical compound CC(N)=O DLFVBJFMPXGRIB-UHFFFAOYSA-N 0.000 description 48
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 42
- 210000004556 brain Anatomy 0.000 description 36
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 30
- 150000003254 radicals Chemical class 0.000 description 30
- 239000004202 carbamide Substances 0.000 description 28
- 239000000203 mixture Substances 0.000 description 28
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 20
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 18
- IKHGUXGNUITLKF-UHFFFAOYSA-N Acetaldehyde Chemical compound CC=O IKHGUXGNUITLKF-UHFFFAOYSA-N 0.000 description 16
- 239000000047 product Substances 0.000 description 15
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 14
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 14
- 208000037259 Amyloid Plaque Diseases 0.000 description 12
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 12
- 238000003818 flash chromatography Methods 0.000 description 12
- 201000010099 disease Diseases 0.000 description 11
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 11
- 210000001320 hippocampus Anatomy 0.000 description 11
- 238000002360 preparation method Methods 0.000 description 11
- 239000011734 sodium Substances 0.000 description 11
- 238000010186 staining Methods 0.000 description 11
- 241000699666 Mus <mouse, genus> Species 0.000 description 10
- 210000005013 brain tissue Anatomy 0.000 description 10
- 239000012267 brine Substances 0.000 description 10
- 239000011541 reaction mixture Substances 0.000 description 10
- HPALAKNZSZLMCH-UHFFFAOYSA-M sodium;chloride;hydrate Chemical compound O.[Na+].[Cl-] HPALAKNZSZLMCH-UHFFFAOYSA-M 0.000 description 10
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 9
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 9
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 9
- 239000012044 organic layer Substances 0.000 description 9
- 238000000746 purification Methods 0.000 description 9
- CSNNHWWHGAXBCP-UHFFFAOYSA-L Magnesium sulfate Chemical compound [Mg+2].[O-][S+2]([O-])([O-])[O-] CSNNHWWHGAXBCP-UHFFFAOYSA-L 0.000 description 8
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 description 8
- 108090000765 processed proteins & peptides Proteins 0.000 description 8
- 239000007787 solid Substances 0.000 description 8
- JDVPQXZIJDEHAN-UHFFFAOYSA-M succinamate Chemical compound NC(=O)CCC([O-])=O JDVPQXZIJDEHAN-UHFFFAOYSA-M 0.000 description 8
- 210000001519 tissue Anatomy 0.000 description 8
- 239000002253 acid Substances 0.000 description 7
- 150000005840 aryl radicals Chemical class 0.000 description 7
- 238000000921 elemental analysis Methods 0.000 description 7
- 210000001353 entorhinal cortex Anatomy 0.000 description 7
- BEBCJVAWIBVWNZ-UHFFFAOYSA-N glycinamide Chemical compound NCC(N)=O BEBCJVAWIBVWNZ-UHFFFAOYSA-N 0.000 description 7
- 230000004770 neurodegeneration Effects 0.000 description 7
- 208000015122 neurodegenerative disease Diseases 0.000 description 7
- DTQVDTLACAAQTR-UHFFFAOYSA-N trifluoroacetic acid Substances OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 description 7
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 6
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 6
- 241000699670 Mus sp. Species 0.000 description 6
- 238000001914 filtration Methods 0.000 description 6
- 230000007170 pathology Effects 0.000 description 6
- 125000004193 piperazinyl group Chemical group 0.000 description 6
- 239000000843 powder Substances 0.000 description 6
- 102000004196 processed proteins & peptides Human genes 0.000 description 6
- 102000004500 CCR1 Receptors Human genes 0.000 description 5
- 108010017319 CCR1 Receptors Proteins 0.000 description 5
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 5
- 239000000032 diagnostic agent Substances 0.000 description 5
- 229940039227 diagnostic agent Drugs 0.000 description 5
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 5
- 239000003550 marker Substances 0.000 description 5
- 239000000463 material Substances 0.000 description 5
- HZAXFHJVJLSVMW-UHFFFAOYSA-N 2-Aminoethan-1-ol Chemical compound NCCO HZAXFHJVJLSVMW-UHFFFAOYSA-N 0.000 description 4
- PAYRUJLWNCNPSJ-UHFFFAOYSA-N Aniline Chemical compound NC1=CC=CC=C1 PAYRUJLWNCNPSJ-UHFFFAOYSA-N 0.000 description 4
- 206010012289 Dementia Diseases 0.000 description 4
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 4
- 208000005314 Multi-Infarct Dementia Diseases 0.000 description 4
- JGFZNNIVVJXRND-UHFFFAOYSA-N N,N-Diisopropylethylamine (DIPEA) Chemical compound CCN(C(C)C)C(C)C JGFZNNIVVJXRND-UHFFFAOYSA-N 0.000 description 4
- GLUUGHFHXGJENI-UHFFFAOYSA-N Piperazine Chemical compound C1CNCCN1 GLUUGHFHXGJENI-UHFFFAOYSA-N 0.000 description 4
- 201000004810 Vascular dementia Diseases 0.000 description 4
- 238000011888 autopsy Methods 0.000 description 4
- RYYVLZVUVIJVGH-UHFFFAOYSA-N caffeine Chemical compound CN1C(=O)N(C)C(=O)C2=C1N=CN2C RYYVLZVUVIJVGH-UHFFFAOYSA-N 0.000 description 4
- 210000003710 cerebral cortex Anatomy 0.000 description 4
- 235000019524 disodium tartrate Nutrition 0.000 description 4
- 239000003480 eluent Substances 0.000 description 4
- 238000004128 high performance liquid chromatography Methods 0.000 description 4
- 230000002962 histologic effect Effects 0.000 description 4
- 239000012216 imaging agent Substances 0.000 description 4
- 150000002500 ions Chemical class 0.000 description 4
- 229910052943 magnesium sulfate Inorganic materials 0.000 description 4
- 235000019341 magnesium sulphate Nutrition 0.000 description 4
- 210000002241 neurite Anatomy 0.000 description 4
- 230000037361 pathway Effects 0.000 description 4
- 125000000951 phenoxy group Chemical group [H]C1=C([H])C([H])=C(O*)C([H])=C1[H] 0.000 description 4
- 229910000027 potassium carbonate Inorganic materials 0.000 description 4
- 201000002212 progressive supranuclear palsy Diseases 0.000 description 4
- QLNJFJADRCOGBJ-UHFFFAOYSA-N propionamide Chemical compound CCC(N)=O QLNJFJADRCOGBJ-UHFFFAOYSA-N 0.000 description 4
- 229910052702 rhenium Inorganic materials 0.000 description 4
- WUAPFZMCVAUBPE-UHFFFAOYSA-N rhenium atom Chemical compound [Re] WUAPFZMCVAUBPE-UHFFFAOYSA-N 0.000 description 4
- 238000010898 silica gel chromatography Methods 0.000 description 4
- HELHAJAZNSDZJO-OLXYHTOASA-L sodium L-tartrate Chemical compound [Na+].[Na+].[O-]C(=O)[C@H](O)[C@@H](O)C([O-])=O HELHAJAZNSDZJO-OLXYHTOASA-L 0.000 description 4
- 239000001433 sodium tartrate Substances 0.000 description 4
- 239000000725 suspension Substances 0.000 description 4
- 229910052713 technetium Inorganic materials 0.000 description 4
- GKLVYJBZJHMRIY-UHFFFAOYSA-N technetium atom Chemical compound [Tc] GKLVYJBZJHMRIY-UHFFFAOYSA-N 0.000 description 4
- AQRLNPVMDITEJU-UHFFFAOYSA-N triethylsilane Chemical compound CC[SiH](CC)CC AQRLNPVMDITEJU-UHFFFAOYSA-N 0.000 description 4
- GETQZCLCWQTVFV-UHFFFAOYSA-N trimethylamine Chemical compound CN(C)C GETQZCLCWQTVFV-UHFFFAOYSA-N 0.000 description 4
- HBAQYPYDRFILMT-UHFFFAOYSA-N 8-[3-(1-cyclopropylpyrazol-4-yl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-3-methyl-3,8-diazabicyclo[3.2.1]octan-2-one Chemical class C1(CC1)N1N=CC(=C1)C1=NNC2=C1N=C(N=C2)N1C2C(N(CC1CC2)C)=O HBAQYPYDRFILMT-UHFFFAOYSA-N 0.000 description 3
- 208000005145 Cerebral amyloid angiopathy Diseases 0.000 description 3
- 102000009410 Chemokine receptor Human genes 0.000 description 3
- 108050000299 Chemokine receptor Proteins 0.000 description 3
- VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 description 3
- 241001354243 Corona Species 0.000 description 3
- 201000011240 Frontotemporal dementia Diseases 0.000 description 3
- XFFSCOOTVXBLCK-QAVVBOBSSA-N OC(=O)c1cc(ccc1O)\N=N\c1ccc(cc1)-c1ccc(cc1)\N=N\c1ccc(O)c(c1)C(O)=O Chemical compound OC(=O)c1cc(ccc1O)\N=N\c1ccc(cc1)-c1ccc(cc1)\N=N\c1ccc(O)c(c1)C(O)=O XFFSCOOTVXBLCK-QAVVBOBSSA-N 0.000 description 3
- 208000018737 Parkinson disease Diseases 0.000 description 3
- 208000000609 Pick Disease of the Brain Diseases 0.000 description 3
- OFOBLEOULBTSOW-UHFFFAOYSA-N Propanedioic acid Natural products OC(=O)CC(O)=O OFOBLEOULBTSOW-UHFFFAOYSA-N 0.000 description 3
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 3
- 125000003545 alkoxy group Chemical group 0.000 description 3
- 239000002585 base Substances 0.000 description 3
- 210000004369 blood Anatomy 0.000 description 3
- 239000008280 blood Substances 0.000 description 3
- 229910052799 carbon Inorganic materials 0.000 description 3
- 239000013522 chelant Substances 0.000 description 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
- 238000013399 early diagnosis Methods 0.000 description 3
- 238000009472 formulation Methods 0.000 description 3
- 125000001188 haloalkyl group Chemical group 0.000 description 3
- 230000002055 immunohistochemical effect Effects 0.000 description 3
- 238000002372 labelling Methods 0.000 description 3
- 238000012986 modification Methods 0.000 description 3
- 230000004048 modification Effects 0.000 description 3
- 210000002569 neuron Anatomy 0.000 description 3
- 238000009206 nuclear medicine Methods 0.000 description 3
- 150000007530 organic bases Chemical class 0.000 description 3
- 239000002953 phosphate buffered saline Substances 0.000 description 3
- 229920001184 polypeptide Polymers 0.000 description 3
- 239000002244 precipitate Substances 0.000 description 3
- 239000012064 sodium phosphate buffer Substances 0.000 description 3
- 238000010532 solid phase synthesis reaction Methods 0.000 description 3
- 239000002904 solvent Substances 0.000 description 3
- 238000012360 testing method Methods 0.000 description 3
- 125000004176 4-fluorobenzyl group Chemical group [H]C1=C([H])C(=C([H])C([H])=C1F)C([H])([H])* 0.000 description 2
- RHWDEIXKHGCDOG-UHFFFAOYSA-N 4-iodo-2-nitrophenol Chemical compound OC1=CC=C(I)C=C1[N+]([O-])=O RHWDEIXKHGCDOG-UHFFFAOYSA-N 0.000 description 2
- QGZKDVFQNNGYKY-UHFFFAOYSA-O Ammonium Chemical compound [NH4+] QGZKDVFQNNGYKY-UHFFFAOYSA-O 0.000 description 2
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 2
- 241000283707 Capra Species 0.000 description 2
- VGCXGMAHQTYDJK-UHFFFAOYSA-N Chloroacetyl chloride Chemical compound ClCC(Cl)=O VGCXGMAHQTYDJK-UHFFFAOYSA-N 0.000 description 2
- XBPCUCUWBYBCDP-UHFFFAOYSA-N Dicyclohexylamine Chemical compound C1CCCCC1NC1CCCCC1 XBPCUCUWBYBCDP-UHFFFAOYSA-N 0.000 description 2
- QOSSAOTZNIDXMA-UHFFFAOYSA-N Dicylcohexylcarbodiimide Chemical compound C1CCCCC1N=C=NC1CCCCC1 QOSSAOTZNIDXMA-UHFFFAOYSA-N 0.000 description 2
- PIICEJLVQHRZGT-UHFFFAOYSA-N Ethylenediamine Chemical compound NCCN PIICEJLVQHRZGT-UHFFFAOYSA-N 0.000 description 2
- VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 description 2
- 206010018341 Gliosis Diseases 0.000 description 2
- 239000004471 Glycine Substances 0.000 description 2
- WZUVPPKBWHMQCE-UHFFFAOYSA-N Haematoxylin Chemical compound C12=CC(O)=C(O)C=C2CC2(O)C1C1=CC=C(O)C(O)=C1OC2 WZUVPPKBWHMQCE-UHFFFAOYSA-N 0.000 description 2
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 2
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 2
- LPHGQDQBBGAPDZ-UHFFFAOYSA-N Isocaffeine Natural products CN1C(=O)N(C)C(=O)C2=C1N(C)C=N2 LPHGQDQBBGAPDZ-UHFFFAOYSA-N 0.000 description 2
- AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 description 2
- 241000283973 Oryctolagus cuniculus Species 0.000 description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 2
- NQRYJNQNLNOLGT-UHFFFAOYSA-N Piperidine Chemical compound C1CCNCC1 NQRYJNQNLNOLGT-UHFFFAOYSA-N 0.000 description 2
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 2
- LCTONWCANYUPML-UHFFFAOYSA-N Pyruvic acid Chemical compound CC(=O)C(O)=O LCTONWCANYUPML-UHFFFAOYSA-N 0.000 description 2
- 108010045517 Serum Amyloid P-Component Proteins 0.000 description 2
- 102100036202 Serum amyloid P-component Human genes 0.000 description 2
- CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 2
- 230000002159 abnormal effect Effects 0.000 description 2
- 230000032683 aging Effects 0.000 description 2
- 150000001412 amines Chemical class 0.000 description 2
- 239000005557 antagonist Substances 0.000 description 2
- 125000003710 aryl alkyl group Chemical group 0.000 description 2
- 210000001130 astrocyte Anatomy 0.000 description 2
- HUMNYLRZRPPJDN-UHFFFAOYSA-N benzenecarboxaldehyde Natural products O=CC1=CC=CC=C1 HUMNYLRZRPPJDN-UHFFFAOYSA-N 0.000 description 2
- WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 2
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 description 2
- 229960001948 caffeine Drugs 0.000 description 2
- VJEONQKOZGKCAK-UHFFFAOYSA-N caffeine Natural products CN1C(=O)N(C)C(=O)C2=C1C=CN2C VJEONQKOZGKCAK-UHFFFAOYSA-N 0.000 description 2
- 239000011575 calcium Substances 0.000 description 2
- 229910052791 calcium Inorganic materials 0.000 description 2
- 230000002490 cerebral effect Effects 0.000 description 2
- OEYIOHPDSNJKLS-UHFFFAOYSA-N choline Chemical compound C[N+](C)(C)CCO OEYIOHPDSNJKLS-UHFFFAOYSA-N 0.000 description 2
- 229960001231 choline Drugs 0.000 description 2
- 230000007423 decrease Effects 0.000 description 2
- HPNMFZURTQLUMO-UHFFFAOYSA-N diethylamine Chemical compound CCNCC HPNMFZURTQLUMO-UHFFFAOYSA-N 0.000 description 2
- NSNHWTBQMQIDCF-UHFFFAOYSA-N dihydrate;hydrochloride Chemical compound O.O.Cl NSNHWTBQMQIDCF-UHFFFAOYSA-N 0.000 description 2
- XBDQKXXYIPTUBI-UHFFFAOYSA-N dimethylselenoniopropionate Natural products CCC(O)=O XBDQKXXYIPTUBI-UHFFFAOYSA-N 0.000 description 2
- 229910001873 dinitrogen Inorganic materials 0.000 description 2
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 2
- 230000000694 effects Effects 0.000 description 2
- 238000011156 evaluation Methods 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 239000000706 filtrate Substances 0.000 description 2
- 239000006260 foam Substances 0.000 description 2
- 230000006870 function Effects 0.000 description 2
- KWIUHFFTVRNATP-UHFFFAOYSA-N glycine betaine Chemical compound C[N+](C)(C)CC([O-])=O KWIUHFFTVRNATP-UHFFFAOYSA-N 0.000 description 2
- 238000011532 immunohistochemical staining Methods 0.000 description 2
- 238000002347 injection Methods 0.000 description 2
- 239000007924 injection Substances 0.000 description 2
- 150000007529 inorganic bases Chemical class 0.000 description 2
- JJWLVOIRVHMVIS-UHFFFAOYSA-N isopropylamine Chemical compound CC(C)N JJWLVOIRVHMVIS-UHFFFAOYSA-N 0.000 description 2
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 2
- BDAGIHXWWSANSR-UHFFFAOYSA-N methanoic acid Natural products OC=O BDAGIHXWWSANSR-UHFFFAOYSA-N 0.000 description 2
- 210000002682 neurofibrillary tangle Anatomy 0.000 description 2
- 229910052757 nitrogen Inorganic materials 0.000 description 2
- QNGNSVIICDLXHT-UHFFFAOYSA-N para-ethylbenzaldehyde Natural products CCC1=CC=C(C=O)C=C1 QNGNSVIICDLXHT-UHFFFAOYSA-N 0.000 description 2
- 150000004885 piperazines Chemical class 0.000 description 2
- 239000011591 potassium Substances 0.000 description 2
- 229910052700 potassium Inorganic materials 0.000 description 2
- BWHMMNNQKKPAPP-UHFFFAOYSA-L potassium carbonate Chemical compound [K+].[K+].[O-]C([O-])=O BWHMMNNQKKPAPP-UHFFFAOYSA-L 0.000 description 2
- YGSDEFSMJLZEOE-UHFFFAOYSA-N salicylic acid Chemical compound OC(=O)C1=CC=CC=C1O YGSDEFSMJLZEOE-UHFFFAOYSA-N 0.000 description 2
- 238000002603 single-photon emission computed tomography Methods 0.000 description 2
- 229910052708 sodium Inorganic materials 0.000 description 2
- 239000012279 sodium borohydride Substances 0.000 description 2
- 229910000033 sodium borohydride Inorganic materials 0.000 description 2
- 125000001424 substituent group Chemical group 0.000 description 2
- 125000003107 substituted aryl group Chemical group 0.000 description 2
- 238000006467 substitution reaction Methods 0.000 description 2
- 208000024891 symptom Diseases 0.000 description 2
- DYHSDKLCOJIUFX-UHFFFAOYSA-N tert-butoxycarbonyl anhydride Chemical compound CC(C)(C)OC(=O)OC(=O)OC(C)(C)C DYHSDKLCOJIUFX-UHFFFAOYSA-N 0.000 description 2
- YAPQBXQYLJRXSA-UHFFFAOYSA-N theobromine Chemical compound CN1C(=O)NC(=O)C2=C1N=CN2C YAPQBXQYLJRXSA-UHFFFAOYSA-N 0.000 description 2
- JOXIMZWYDAKGHI-UHFFFAOYSA-N toluene-4-sulfonic acid Chemical compound CC1=CC=C(S(O)(=O)=O)C=C1 JOXIMZWYDAKGHI-UHFFFAOYSA-N 0.000 description 2
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 2
- ITMCEJHCFYSIIV-UHFFFAOYSA-M triflate Chemical compound [O-]S(=O)(=O)C(F)(F)F ITMCEJHCFYSIIV-UHFFFAOYSA-M 0.000 description 2
- QBYIENPQHBMVBV-HFEGYEGKSA-N (2R)-2-hydroxy-2-phenylacetic acid Chemical compound O[C@@H](C(O)=O)c1ccccc1.O[C@@H](C(O)=O)c1ccccc1 QBYIENPQHBMVBV-HFEGYEGKSA-N 0.000 description 1
- JOMNTHCQHJPVAZ-RXMQYKEDSA-N (2r)-2-methylpiperazine Chemical compound C[C@@H]1CNCCN1 JOMNTHCQHJPVAZ-RXMQYKEDSA-N 0.000 description 1
- RYHBNJHYFVUHQT-UHFFFAOYSA-N 1,4-Dioxane Chemical compound C1COCCO1 RYHBNJHYFVUHQT-UHFFFAOYSA-N 0.000 description 1
- IZXWCDITFDNEBY-UHFFFAOYSA-N 1-(chloromethyl)-4-fluorobenzene Chemical compound FC1=CC=C(CCl)C=C1 IZXWCDITFDNEBY-UHFFFAOYSA-N 0.000 description 1
- 125000004973 1-butenyl group Chemical group C(=CCC)* 0.000 description 1
- HVTUHSABWJPWNK-UHFFFAOYSA-N 2-[2-chloro-5-[3-(5-chlorospiro[3h-1-benzofuran-2,4'-piperidine]-1'-yl)-2-hydroxypropoxy]-4-(methylcarbamoyl)phenoxy]-2-methylpropanoic acid Chemical compound CNC(=O)C1=CC(Cl)=C(OC(C)(C)C(O)=O)C=C1OCC(O)CN1CCC2(OC3=CC=C(Cl)C=C3C2)CC1 HVTUHSABWJPWNK-UHFFFAOYSA-N 0.000 description 1
- MSWZFWKMSRAUBD-IVMDWMLBSA-N 2-amino-2-deoxy-D-glucopyranose Chemical compound N[C@H]1C(O)O[C@H](CO)[C@@H](O)[C@@H]1O MSWZFWKMSRAUBD-IVMDWMLBSA-N 0.000 description 1
- SWFNPENEBHAHEB-UHFFFAOYSA-N 2-amino-4-chlorophenol Chemical compound NC1=CC(Cl)=CC=C1O SWFNPENEBHAHEB-UHFFFAOYSA-N 0.000 description 1
- BFSVOASYOCHEOV-UHFFFAOYSA-N 2-diethylaminoethanol Chemical compound CCN(CC)CCO BFSVOASYOCHEOV-UHFFFAOYSA-N 0.000 description 1
- 229940013085 2-diethylaminoethanol Drugs 0.000 description 1
- AUFVJZSDSXXFOI-UHFFFAOYSA-N 2.2.2-cryptand Chemical compound C1COCCOCCN2CCOCCOCCN1CCOCCOCC2 AUFVJZSDSXXFOI-UHFFFAOYSA-N 0.000 description 1
- BMYNFMYTOJXKLE-UHFFFAOYSA-N 3-azaniumyl-2-hydroxypropanoate Chemical compound NCC(O)C(O)=O BMYNFMYTOJXKLE-UHFFFAOYSA-N 0.000 description 1
- OSWFIVFLDKOXQC-UHFFFAOYSA-N 4-(3-methoxyphenyl)aniline Chemical compound COC1=CC=CC(C=2C=CC(N)=CC=2)=C1 OSWFIVFLDKOXQC-UHFFFAOYSA-N 0.000 description 1
- NWSIFTLPLKCTSX-UHFFFAOYSA-N 4-chloro-2-nitrophenol Chemical compound OC1=CC=C(Cl)C=C1[N+]([O-])=O NWSIFTLPLKCTSX-UHFFFAOYSA-N 0.000 description 1
- 125000006283 4-chlorobenzyl group Chemical group [H]C1=C([H])C(=C([H])C([H])=C1Cl)C([H])([H])* 0.000 description 1
- VSMDINRNYYEDRN-UHFFFAOYSA-N 4-iodophenol Chemical compound OC1=CC=C(I)C=C1 VSMDINRNYYEDRN-UHFFFAOYSA-N 0.000 description 1
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 1
- 102000013455 Amyloid beta-Peptides Human genes 0.000 description 1
- 108010090849 Amyloid beta-Peptides Proteins 0.000 description 1
- 239000004475 Arginine Substances 0.000 description 1
- 239000005711 Benzoic acid Substances 0.000 description 1
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 1
- 206010061818 Disease progression Diseases 0.000 description 1
- 102100039289 Glial fibrillary acidic protein Human genes 0.000 description 1
- 101710193519 Glial fibrillary acidic protein Proteins 0.000 description 1
- 101000934372 Homo sapiens Macrosialin Proteins 0.000 description 1
- ZCYVEMRRCGMTRW-AHCXROLUSA-N Iodine-123 Chemical compound [123I] ZCYVEMRRCGMTRW-AHCXROLUSA-N 0.000 description 1
- ODKSFYDXXFIFQN-BYPYZUCNSA-P L-argininium(2+) Chemical compound NC(=[NH2+])NCCC[C@H]([NH3+])C(O)=O ODKSFYDXXFIFQN-BYPYZUCNSA-P 0.000 description 1
- HNDVDQJCIGZPNO-YFKPBYRVSA-N L-histidine Chemical compound OC(=O)[C@@H](N)CC1=CN=CN1 HNDVDQJCIGZPNO-YFKPBYRVSA-N 0.000 description 1
- KDXKERNSBIXSRK-YFKPBYRVSA-N L-lysine Chemical compound NCCCC[C@H](N)C(O)=O KDXKERNSBIXSRK-YFKPBYRVSA-N 0.000 description 1
- 208000009829 Lewy Body Disease Diseases 0.000 description 1
- 201000002832 Lewy body dementia Diseases 0.000 description 1
- WHXSMMKQMYFTQS-UHFFFAOYSA-N Lithium Chemical compound [Li] WHXSMMKQMYFTQS-UHFFFAOYSA-N 0.000 description 1
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 1
- 239000004472 Lysine Substances 0.000 description 1
- 102100025136 Macrosialin Human genes 0.000 description 1
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 1
- 102000018697 Membrane Proteins Human genes 0.000 description 1
- 108010052285 Membrane Proteins Proteins 0.000 description 1
- 102000014415 Muscarinic acetylcholine receptor Human genes 0.000 description 1
- 108050003473 Muscarinic acetylcholine receptor Proteins 0.000 description 1
- UEEJHVSXFDXPFK-UHFFFAOYSA-N N-dimethylaminoethanol Chemical compound CN(C)CCO UEEJHVSXFDXPFK-UHFFFAOYSA-N 0.000 description 1
- MBBZMMPHUWSWHV-BDVNFPICSA-N N-methylglucamine Chemical compound CNC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO MBBZMMPHUWSWHV-BDVNFPICSA-N 0.000 description 1
- 102400000108 N-terminal peptide Human genes 0.000 description 1
- 101800000597 N-terminal peptide Proteins 0.000 description 1
- 229910020889 NaBH3 Inorganic materials 0.000 description 1
- 102000008763 Neurofilament Proteins Human genes 0.000 description 1
- 108010088373 Neurofilament Proteins Proteins 0.000 description 1
- GRYLNZFGIOXLOG-UHFFFAOYSA-N Nitric acid Chemical compound O[N+]([O-])=O GRYLNZFGIOXLOG-UHFFFAOYSA-N 0.000 description 1
- CTQNGGLPUBDAKN-UHFFFAOYSA-N O-Xylene Chemical compound CC1=CC=CC=C1C CTQNGGLPUBDAKN-UHFFFAOYSA-N 0.000 description 1
- 238000012879 PET imaging Methods 0.000 description 1
- 208000037273 Pathologic Processes Diseases 0.000 description 1
- 102000003992 Peroxidases Human genes 0.000 description 1
- IWYDHOAUDWTVEP-UHFFFAOYSA-N R-2-phenyl-2-hydroxyacetic acid Natural products OC(=O)C(O)C1=CC=CC=C1 IWYDHOAUDWTVEP-UHFFFAOYSA-N 0.000 description 1
- KDYFGRWQOYBRFD-UHFFFAOYSA-N Succinic acid Natural products OC(=O)CCC(O)=O KDYFGRWQOYBRFD-UHFFFAOYSA-N 0.000 description 1
- FEWJPZIEWOKRBE-UHFFFAOYSA-N Tartaric acid Natural products [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-N 0.000 description 1
- 229920004890 Triton X-100 Polymers 0.000 description 1
- HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 description 1
- FDFIMJICTKKXAY-SECBINFHSA-N [5-chloro-2-[2-[(2r)-2-methylpiperazin-1-yl]-2-oxoethoxy]phenyl]urea Chemical compound C[C@@H]1CNCCN1C(=O)COC1=CC=C(Cl)C=C1NC(N)=O FDFIMJICTKKXAY-SECBINFHSA-N 0.000 description 1
- YQKFJYBRZVNXKQ-UHFFFAOYSA-N [Na].BC#N Chemical compound [Na].BC#N YQKFJYBRZVNXKQ-UHFFFAOYSA-N 0.000 description 1
- 150000007513 acids Chemical class 0.000 description 1
- 239000002671 adjuvant Substances 0.000 description 1
- 125000003342 alkenyl group Chemical group 0.000 description 1
- AZDRQVAHHNSJOQ-UHFFFAOYSA-N alumane Chemical class [AlH3] AZDRQVAHHNSJOQ-UHFFFAOYSA-N 0.000 description 1
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- VZTDIZULWFCMLS-UHFFFAOYSA-N ammonium formate Chemical compound [NH4+].[O-]C=O VZTDIZULWFCMLS-UHFFFAOYSA-N 0.000 description 1
- 230000003941 amyloidogenesis Effects 0.000 description 1
- 206010002022 amyloidosis Diseases 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 238000005349 anion exchange Methods 0.000 description 1
- 229940121363 anti-inflammatory agent Drugs 0.000 description 1
- 239000002260 anti-inflammatory agent Substances 0.000 description 1
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 1
- 229960003121 arginine Drugs 0.000 description 1
- WZSUOQDIYKMPMT-UHFFFAOYSA-N argon krypton Chemical compound [Ar].[Kr] WZSUOQDIYKMPMT-UHFFFAOYSA-N 0.000 description 1
- 208000037875 astrocytosis Diseases 0.000 description 1
- 230000007341 astrogliosis Effects 0.000 description 1
- 235000010233 benzoic acid Nutrition 0.000 description 1
- 125000000440 benzylamino group Chemical group [H]N(*)C([H])([H])C1=C([H])C([H])=C([H])C([H])=C1[H] 0.000 description 1
- MSWZFWKMSRAUBD-UHFFFAOYSA-N beta-D-galactosamine Natural products NC1C(O)OC(CO)C(O)C1O MSWZFWKMSRAUBD-UHFFFAOYSA-N 0.000 description 1
- 229960003237 betaine Drugs 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 230000000903 blocking effect Effects 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- KDYFGRWQOYBRFD-NUQCWPJISA-N butanedioic acid Chemical compound O[14C](=O)CC[14C](O)=O KDYFGRWQOYBRFD-NUQCWPJISA-N 0.000 description 1
- 238000004364 calculation method Methods 0.000 description 1
- 238000012754 cardiac puncture Methods 0.000 description 1
- 210000004027 cell Anatomy 0.000 description 1
- 210000005056 cell body Anatomy 0.000 description 1
- 230000036755 cellular response Effects 0.000 description 1
- NCEXYHBECQHGNR-UHFFFAOYSA-N chembl421 Chemical compound C1=C(O)C(C(=O)O)=CC(N=NC=2C=CC(=CC=2)S(=O)(=O)NC=2N=CC=CC=2)=C1 NCEXYHBECQHGNR-UHFFFAOYSA-N 0.000 description 1
- 235000015165 citric acid Nutrition 0.000 description 1
- 238000003759 clinical diagnosis Methods 0.000 description 1
- 230000006999 cognitive decline Effects 0.000 description 1
- 208000010877 cognitive disease Diseases 0.000 description 1
- 238000012790 confirmation Methods 0.000 description 1
- 238000004624 confocal microscopy Methods 0.000 description 1
- IQFVPQOLBLOTPF-HKXUKFGYSA-L congo red Chemical class [Na+].[Na+].C1=CC=CC2=C(N)C(/N=N/C3=CC=C(C=C3)C3=CC=C(C=C3)/N=N/C3=C(C4=CC=CC=C4C(=C3)S([O-])(=O)=O)N)=CC(S([O-])(=O)=O)=C21 IQFVPQOLBLOTPF-HKXUKFGYSA-L 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- 230000005786 degenerative changes Effects 0.000 description 1
- 238000013461 design Methods 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 230000018109 developmental process Effects 0.000 description 1
- 125000001028 difluoromethyl group Chemical group [H]C(F)(F)* 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- 230000005750 disease progression Effects 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 230000008030 elimination Effects 0.000 description 1
- 238000003379 elimination reaction Methods 0.000 description 1
- CCIVGXIOQKPBKL-UHFFFAOYSA-M ethanesulfonate Chemical compound CCS([O-])(=O)=O CCIVGXIOQKPBKL-UHFFFAOYSA-M 0.000 description 1
- 239000002024 ethyl acetate extract Substances 0.000 description 1
- 229940012017 ethylenediamine Drugs 0.000 description 1
- 125000001153 fluoro group Chemical group F* 0.000 description 1
- 235000019253 formic acid Nutrition 0.000 description 1
- 239000012458 free base Substances 0.000 description 1
- 210000005153 frontal cortex Anatomy 0.000 description 1
- 239000001530 fumaric acid Substances 0.000 description 1
- 235000011087 fumaric acid Nutrition 0.000 description 1
- 239000007789 gas Substances 0.000 description 1
- 238000007429 general method Methods 0.000 description 1
- 210000005046 glial fibrillary acidic protein Anatomy 0.000 description 1
- 230000007387 gliosis Effects 0.000 description 1
- 229960002442 glucosamine Drugs 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 125000004438 haloalkoxy group Chemical group 0.000 description 1
- 230000000971 hippocampal effect Effects 0.000 description 1
- HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 description 1
- 229960002885 histidine Drugs 0.000 description 1
- 230000001744 histochemical effect Effects 0.000 description 1
- XGIHQYAWBCFNPY-AZOCGYLKSA-N hydrabamine Chemical compound C([C@@H]12)CC3=CC(C(C)C)=CC=C3[C@@]2(C)CCC[C@@]1(C)CNCCNC[C@@]1(C)[C@@H]2CCC3=CC(C(C)C)=CC=C3[C@@]2(C)CCC1 XGIHQYAWBCFNPY-AZOCGYLKSA-N 0.000 description 1
- 239000005457 ice water Substances 0.000 description 1
- 238000003384 imaging method Methods 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 238000000099 in vitro assay Methods 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 238000005462 in vivo assay Methods 0.000 description 1
- 230000003834 intracellular effect Effects 0.000 description 1
- 239000003456 ion exchange resin Substances 0.000 description 1
- 229920003303 ion-exchange polymer Polymers 0.000 description 1
- NIZHERJWXFHGGU-UHFFFAOYSA-N isocyanato(trimethyl)silane Chemical compound C[Si](C)(C)N=C=O NIZHERJWXFHGGU-UHFFFAOYSA-N 0.000 description 1
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
- 210000004731 jugular vein Anatomy 0.000 description 1
- 239000004310 lactic acid Substances 0.000 description 1
- 235000014655 lactic acid Nutrition 0.000 description 1
- 210000000265 leukocyte Anatomy 0.000 description 1
- 229910052744 lithium Inorganic materials 0.000 description 1
- 230000004807 localization Effects 0.000 description 1
- 229960003646 lysine Drugs 0.000 description 1
- 210000002540 macrophage Anatomy 0.000 description 1
- 239000011777 magnesium Substances 0.000 description 1
- 229910052749 magnesium Inorganic materials 0.000 description 1
- 159000000003 magnesium salts Chemical class 0.000 description 1
- VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 description 1
- 239000011976 maleic acid Substances 0.000 description 1
- 229960002510 mandelic acid Drugs 0.000 description 1
- 230000001404 mediated effect Effects 0.000 description 1
- BRMYZIKAHFEUFJ-UHFFFAOYSA-L mercury diacetate Chemical compound CC(=O)O[Hg]OC(C)=O BRMYZIKAHFEUFJ-UHFFFAOYSA-L 0.000 description 1
- 229940098779 methanesulfonic acid Drugs 0.000 description 1
- 230000002025 microglial effect Effects 0.000 description 1
- 238000000386 microscopy Methods 0.000 description 1
- 150000007522 mineralic acids Chemical class 0.000 description 1
- 238000000329 molecular dynamics simulation Methods 0.000 description 1
- 210000005044 neurofilament Anatomy 0.000 description 1
- 230000005015 neuronal process Effects 0.000 description 1
- 231100000189 neurotoxic Toxicity 0.000 description 1
- 230000002887 neurotoxic effect Effects 0.000 description 1
- 229910017604 nitric acid Inorganic materials 0.000 description 1
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 description 1
- 230000009871 nonspecific binding Effects 0.000 description 1
- 150000007524 organic acids Chemical class 0.000 description 1
- 235000005985 organic acids Nutrition 0.000 description 1
- FJKROLUGYXJWQN-UHFFFAOYSA-N papa-hydroxy-benzoic acid Natural products OC(=O)C1=CC=C(O)C=C1 FJKROLUGYXJWQN-UHFFFAOYSA-N 0.000 description 1
- 238000012335 pathological evaluation Methods 0.000 description 1
- 230000009054 pathological process Effects 0.000 description 1
- 108040007629 peroxidase activity proteins Proteins 0.000 description 1
- 230000036470 plasma concentration Effects 0.000 description 1
- 229920000768 polyamine Polymers 0.000 description 1
- GKKCIDNWFBPDBW-UHFFFAOYSA-M potassium cyanate Chemical compound [K]OC#N GKKCIDNWFBPDBW-UHFFFAOYSA-M 0.000 description 1
- 238000011533 pre-incubation Methods 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 150000003141 primary amines Chemical class 0.000 description 1
- MFDFERRIHVXMIY-UHFFFAOYSA-N procaine Chemical compound CCN(CC)CCOC(=O)C1=CC=C(N)C=C1 MFDFERRIHVXMIY-UHFFFAOYSA-N 0.000 description 1
- 229960004919 procaine Drugs 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 235000019260 propionic acid Nutrition 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 150000003212 purines Chemical class 0.000 description 1
- 229940107700 pyruvic acid Drugs 0.000 description 1
- 238000011002 quantification Methods 0.000 description 1
- 238000011158 quantitative evaluation Methods 0.000 description 1
- IUVKMZGDUIUOCP-BTNSXGMBSA-N quinbolone Chemical compound O([C@H]1CC[C@H]2[C@H]3[C@@H]([C@]4(C=CC(=O)C=C4CC3)C)CC[C@@]21C)C1=CCCC1 IUVKMZGDUIUOCP-BTNSXGMBSA-N 0.000 description 1
- 230000005855 radiation Effects 0.000 description 1
- 239000000700 radioactive tracer Substances 0.000 description 1
- 239000002287 radioligand Substances 0.000 description 1
- 238000010992 reflux Methods 0.000 description 1
- 239000011347 resin Substances 0.000 description 1
- 229920005989 resin Polymers 0.000 description 1
- 229960004889 salicylic acid Drugs 0.000 description 1
- 150000003335 secondary amines Chemical class 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 1
- 229910000029 sodium carbonate Inorganic materials 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- ZIQRIAYNHAKDDU-UHFFFAOYSA-N sodium;hydroiodide Chemical compound [Na].I ZIQRIAYNHAKDDU-UHFFFAOYSA-N 0.000 description 1
- 238000007447 staining method Methods 0.000 description 1
- 238000010561 standard procedure Methods 0.000 description 1
- 230000001954 sterilising effect Effects 0.000 description 1
- 238000004659 sterilization and disinfection Methods 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
- 125000000547 substituted alkyl group Chemical group 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- 230000007470 synaptic degeneration Effects 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 230000009897 systematic effect Effects 0.000 description 1
- 229940066771 systemic antihistamines piperazine derivative Drugs 0.000 description 1
- 239000011975 tartaric acid Substances 0.000 description 1
- 235000002906 tartaric acid Nutrition 0.000 description 1
- 102000013498 tau Proteins Human genes 0.000 description 1
- 108010026424 tau Proteins Proteins 0.000 description 1
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- 150000003512 tertiary amines Chemical class 0.000 description 1
- 229960004559 theobromine Drugs 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 125000003866 trichloromethyl group Chemical group ClC(Cl)(Cl)* 0.000 description 1
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 description 1
- YFTHZRPMJXBUME-UHFFFAOYSA-N tripropylamine Chemical compound CCCN(CCC)CCC YFTHZRPMJXBUME-UHFFFAOYSA-N 0.000 description 1
- 230000003827 upregulation Effects 0.000 description 1
- 125000000391 vinyl group Chemical group [H]C([*])=C([H])[H] 0.000 description 1
- 238000012800 visualization Methods 0.000 description 1
- 239000008096 xylene Substances 0.000 description 1
- 229910052725 zinc Inorganic materials 0.000 description 1
- 239000011701 zinc Substances 0.000 description 1
Description
Radiopharmaceuticals for Diagnosing Alzheimer's Disease
Field of the invention
The present invention relates to novel radiopharmaceuticals useful for the diagnosis of
Alzheimer's disease.
Brief description of the background art
Alzheimer's disease is a severe neurodegenerative disorder, and currently about 4 million Americans suffer from this disease. As the aging population continues to grow, this number could reach 14 million by the middle of next century unless a cure or prevention is found. At present, there is no sensitive and specific premortem test for early diagnosis of this disease. Alzheimer's disease is currently diagnosed based on the clinical observation of cognitive decline, coupled with the systematic elimination of other possible causes of those symptoms. The confirmation of the clinical diagnosis of "probable Alzheimer's disease" can only be made by examination of the postmortem brain. The Alzheimer's disease brain is characterized by the appearance of two distinct abnormal proteinaceous deposits in regions of the brain responsible for learning and memory (e.g., cerebral cortex and hippocampus). These deposits are extracellular amyloid plaques, which are characteristic of Alzheimer's disease, and intracellular neurofibillary tangles (NFTs), which can be found in other neurodegenerative disorders as well. Amyloid peptides are typically either 40 or 42 amino acids in length ("Aβ1"40" or "Aβ1"42", respectively) and are formed from abnormal processing of a larger membrane-associated protein of unknown function, the amyloid precurser protein ("APP"). Oligomeric aggregates of these peptides are thought to be neurotoxic, eventually resulting in synaptic degeneration and neuronal loss. The amount of amyloid deposition roughly correlates with the severity of symptoms at the time of death.
In the past, there have been several attempts for the design of radiopharmaceuticals that could be used as diagnostic agents for a premortem diagnosis of Alzheimer's disease. Bornebroek et al. showed that the amyloid-associated protein serum amyloid P
component (SAP), labeled with 1231, accumulates at low levels in the cerebral cortex, possibly in vessel walls, of patients with cerebral amyloidosis (Bornebroek, M., et al., Nucl. Med. Commun. (1996), Vol. 17, pp. 929-933).
Saito et al. proposed a vector-mediated delivery of 125l-labeled Aβ1"40 through the blood-brain barrier. It is reported that the iodinated Aβ1"40 binds Aβ amyloid plaque in tissue sections (Saito, Y., etal., Proc. Natl. Acad. Sci. USA 1995, Vol. 92, pp.10227-10231 ).
U.S. Patent No. 5,231 ,000 discloses antibodies with specificity to A4 amyloid polypeptide found in the brain of Alzheimer's disease patients. However, a method to deliver these antibodies across the blood-brain barrier has not been described. Zhen et al. described modifications of the amyloid-binding dye known as "Congo
Red™", and complexes of these modified molecules with technetium and rhenium. The complexes with radioactive ions are purported to be potential imaging agents for Alzheimer's disease (Zhen etal., J. Med. Chem.(W99), Vol. 42, pp. 2805-2815). However, the potential of the complexes to cross the blood-brain barrier is limited. A group at the University of Pennsylvania in the U.S.A. (Skovronsky, M., et al., Proc.
Natl. Acad. Sci. 2000, Vol. 97, pp.7609-7614) has developed a fluorescently labeled derivative of Congo Red that is brain permeable and that non-specifically binds to amyloid materials (that is, peptides in β-pleated sheet conformation). This compound would need to be radiolabeled and then run through pre-clinical screens for pharmacokinetics and toxicity before clinical testing.
Klunk etal. reported experiments with a derivative of Congo Red™, Chrysamine G (CG). It is reported that CG binds synthetic β-amyloid well in vitro, and crosses the blood- brain barrier in normal mice (Klunk etal., Neurobiol. Aging (1994), Vol. 15, No. 6, pp. 691- 698). Bergstrόm etal. presented a compound labeled with iodine-123 as a potential radioligand for visualization of i and M2 muscarinic acetylcholine receptors in Alzheimer's disease (Bergstrόm etal., Eur. J. Nucl. Med. (1999), Vol. 26, pp. 1482-1485 ).
Recently, it has been discovered that certain specific chemokine receptors are upregulated in the brains of patients with Alzheimer's disease (Horuk, R. etal., J. Immunol. (1997), Vol. 158, pp. 2882-2890); Xia etal., J. NeuroVirol. (1999), Vol. 5, pp. 32-41). In
addition, it has been shown recently that the chemokine receptor CCR1 is upregulated in the brains of patients with advanced Alzheimer's disease and absent in normal-aged brains (Halks-Miller etal, CCR1 Immunoreactivity in Alzheimer's Disease Brains, Society for Neuroscience Meeting Abstract, #787.6, Volume 24, 1998). Antagonists to the CCR1 receptor and their use as anti-inflammatory agents are described in the PCT Published Patent Application, WO 98/56771.
None of the above described proposals have resulted in a clinical development of an imaging agent for the early diagnosis of Alzheimer's disease. Accordingly, there is still a clinical need for a diagnostic agent that could be used for a reliable and early diagnosis of Alzheimer's disease.
SUMMARY OF THE INVENTION
The present invention is directed to radiopharmaceuticals that bind to the CCR1 receptor and are able to pass through the blood-brain barrier, and are therefore useful in diagnosing Alzheimer's disease, preferably at an early stage of the disease.
Accordingly, in one aspect, the invention is directed to compounds of formula (I):
wherein: X1 and X2 are each independently halo;
R1 and R2 are each independently hydrogen or alkyl; and R3 is hydrogen, amino, monoalkylamino, dialkylamino, monoaralkylamino, alkylcarbonylamino, alkenylcarbonylamino, haloalkylcarbonylamino, arylcarbonylamino, alkoxyalkylcarbonylamino, alkoxycarbonylalkylcarbonylamino,
glycinamido, monoalkylglycinamido, arylcarbonylglycinamido, aminocarbonylglycinamido, (aminocarbonyl)(alkyl)glycinamido, (alkoxyalkylcarbonyl)glycinamido, ureido, monoalkylureido, monoarylureido, monoaralkylureido, or alaninamido; and wherein either one of X1 or X2 is selected from the group of 123l, 125l, 128l, 131l, 75Br, 76Br, 80Br and 18F; or wherein one of the carbon atoms in the compound is 11C; or a pharmaceutically acceptable salt thereof.
In another aspect, the invention is directed to compounds of formula (II):
wherein
X1 and X2 are each independently halo; R1 and R2 are each independently hydrogen or alkyl; and R4 is hydrogen; and R5 comprises a chelator capable of binding a radioactive metal atom chosen from the group of 99mTc, 186Re and 188Re; or as a complex with 99mTc, 186Re and 188Re; or a pharmaceutically acceptable salt thereof.
In another aspect, this invention is directed to a method of diagnosing Alzheimer's disease in a human which comprises administering to a human in need of such diagnosis a compound of formula (I) or formula (II), as described above and herein, and measuring the radioactivity arising from the administration of the compound to the human either by using a gamma camera or by positron emission tomography (PET).
In another aspect, the invention is directed to a method of using a compound of the
invention for the manufacture of a radiopharmaceutical for the diagnosis of Alzheimer's disease in a human.
In another aspect, the invention is directed to a method of preparing compounds of the invention.
Brief Description of the Figures
Figure 1 shows the expression of CCR1 in Alzheimer's disease brain tissue .
Figure 2 shows CCR1 antibody specificity in Alzheimer's disease brain tissue. Figure 3 shows CCR1 -Aβ1"40 double-labeled tissue sections
Figure 4 shows neuritic plaques double-labeled for CCR1 and Aβ1"42.
Figure 5 shows diffuse Aβ1"42 staining in Alzheimer's disease brain.
Figure 6 is a graph showing the relationship between CCR1 and Aβ1"40 by CDR score.
Figure 7 is a graph showing the relationship between CCR1 and Aβ1"42 by CDR score. Figure 8 is a graph demonstrating the decrease in total brain radioactivity over time.
Figure 9 is a graph showing the percent of injected dose in brain and plasma.
Figure 10 are graphs showing CCR1 expression in other neurodegenerative diseases.
Detailed Description of the Invention Definitions
As used in the specification and appended claims, unless specified to the contrary, the following terms have the meaning indicated:
"Alkyl" refers to a straight or branched chain monovalent or divalent radical consisting solely of carbon and hydrogen, containing no unsaturation and having from one to eight carbon atoms, e.g., methyl, ethyl, π-propyl, 1 -methylethyl (/so-propyl), π-butyl, π-pentyl, 1 ,1-dimethylethyl (f-butyl), π-heptyl, and the like.
"Alkylcarbonylamino" refers to a radical of the formula -N(H)-C(0)-Ra where Ra is an alkyl radical as defined above, e.g., acetylamino, ethylcarbonylamino, π-propylcarbonylamino, and the like. "Alkenyl" refers to a straight or branched chain monovalent or divalent radical
consisting solely of carbon and hydrogen, containing at least one double bond and having from two to eight carbon atoms, e.g., ethenyl, prop-1-enyl, but-1-enyl, pent-1-enyl, penta-1 ,4-dienyl, and the like.
"Alkenylcarbonylamino" refers to a radical of the formula -N(H)-C(0)-Rc where Rc is an alkenyl radical as defined above, e.g., ethenylcarbonylamino, prop-2-enylcarbonylamino, but-2-enylcarbonylamino, and the like.
"Alkoxy" refers to a radical of the formula -ORa where Ra is an alkyl radical as defined above, e.g., methoxy, ethoxy, π-propoxy, 1 -methylethoxy (/so-propoxy), π-butoxy, π-pentoxy, 1 ,1-dimethylethoxy (f-butoxy), and the like. "Alkoxycarbonylalkylcarbonylamino" refers to a radical of the formula
-N(H)-C(0)-Ra-C(0)ORa where each Ra is independently an alkyl radical as defined above, e.g., ethoxycarbonylmethylcarbonylamino, methoxycarbonylmethylcarbonylamino, (2-ethoxycarbonylethyl)carbonylamino, (2-methoxycarbonylethyl)carbonylamino, and the like.
"(Alkoxyalkylcarbonyl)glycinamido" refers to a radical of the formula -N(H)-C(0)-CH2- N(H)-C(0)-Ra-0-Ra where each Ra is independently an alkyl radical as defined above, e.g., (methoxyacetyl)glycinamido, (ethoxyacetyl)glycinamido, and the like.
"Amino" refers to the radical -NH2.
"Aminocarbonylglycinamido" refers to a radical of the formula -N(H)-C(0)-CH2-N(H)- C(0)-NH2. "(AminocarbonyI)(alkyl)glycinamido" refers to a radical of the formula
-N(H)-C(0)-CH2-N(Ra)-C(0)-NH2 where Ra is an alkyl radical as defined above.
"Aryl" refers to a phenyl or naphthyl radical. Unless stated otherwise specifically in the specification, the term "aryl" or the prefix "ar-" (such as in "aralkyl") is meant to include aryl radicals optionally substituted by one or more substituents selected from the group consisting of halo, alkyl, alkoxy, haloalkyl, haloalkoxy, nitro, amino, monoalkylamino, and dialkylamino, as defined herein.
"Arylcarbonylamino" refers to a radical of the formula -N(H)-C(0)-Rb where Rb is an aryl radical as defined above, e.g., (4-methoxyphenyl)carbonylamino, (4-fluorophenyl)carbonylamino, (4-chlorophenyl)carbonylamino, and the like. "Arylcarbonylglycinamido" refers to a radical of the formula
-N(H)-C(0)-CH2-N(H)-C(0)-Rb where R is an aryl radical as defined above, e.g., phenylcarbonylglycinamido, (4-fluoro-3-trifluoromethylphenyl)carbonylglycinamido, (4-fluorophenyl)carbonylglycinamido, and the like.
"Aralkyl" refers to a radical of the formula -RaRb where Ra is an alkyl radical as defined above and Rb is an aryl radical as defined above, e.g., benzyl, and the like.
"Alkoxyalkylcarbonylamino" refers to a radical of the formula -N(H)-C(0)-Ra-0-Ra where each Ra is an alkyl radical as defined above, e.g., methoxymethylcarbonylamino, ethoxyethylcarbonylamino, methoxyethylcarbonylamino, and the like.
"Alaninamido" refers to a radical of the formula -N(H)-C(0)-C(CH3)H-NH2. "Benzyl" refers to a radical of the formula -CH2-Rh where Rh is a phenyl radical optionally substituted by one or more substituents selected from the group consisting of halo, alkyl, haloalkyl, alkoxy, nitro, amino, monoalkylamino, and dialkylamino.
"Dialkylamino" refers to a radical of the formula -N(Ra)Ra where each Ra is independently an alkyl radical as defined above, e.g., dimethylamino, methylethylamino, diethylamino, dipropylamino, ethylpropylamino, and the like.
"Glycinamido" refers to a radical of the formula -N(H)-C(0)-CH2-NH2.
"Halo" refers to bromo, chloro, iodo or fluoro.
"Haloalkyl" refers to an alkyl radical, as defined above, that is substituted by one or more halo radicals, as defined above, e.g., trifluoromethyl, difluoromethyl, trichloromethyl, 2-trifluoroethyl, 1-fluoromethyl-2-fluoroethyl, 3-bromo-2-fIuoropropyl, 1-bromomethyl-2-bromoethyl, and the like.
"Haloalkylcarbonylamino" refers to a radical of the formula -N(H)-C(0)-Rf where Rf is an haloalkyl radical as defined above, e.g., trifluoromethylcarbonylamino, trifluoromethylcarbonylamino, 2-bromoethylcarbonylamino, and the like. "Monoalkylamino" refers to a radical of the formula -N(H)Ra where Ra is an alkyl radical as defined above, e.g., methylamino, ethylamino, propylamino, and the like.
"Monoaralkylamino" refers to a radical of the formula -N(H)Rd where Rd is an aralkyl radical as defined above, e.g., benzylamino, (3,4,5-trimethoxybenzyl)amino, (4-chlorobenzyl)amino,and the like. "Monoalkylglycinamido" refers to a radical of the formula -N(H)-C(0)-CH2-N(H)Ra
where Ra is an alkyl radical as defined above.
"Monoalkylureido" refers to a radical of the formula -N(H)-C(0)-N(H)Ra or a radical of the formula -N(Ra)-C(0)-NH2 where Ra is an alkyl radical as defined above.
"Monoarylureido" refers to a radical of the formula -N(H)-C(0)-N(H)Rb or a radical of the formula -N(Rb)-C(0)-NH2 where Rb is an aryl radical as defined above
"Monoaralkylureido" refers to a radical of the formula -N(H)-C(0)-N(H)Rd or a radical of the formula -N(Rd)-C(0)-NH2 where Rd is an aralkyl radical as defined above.
"Optional" or "optionally" means that the subsequently described event of circumstances may or may not occur, and that the description includes instances where said event or circumstance occurs and instances in which it does not. For example, "optionally substituted aryl" means that the aryl radical may or may not be substituted and that the description includes both substituted aryl radicals and aryl radicals having no substitution.
"Pharmaceutically acceptable salt" includes both acid and base addition salts.
"Pharmaceutically acceptable acid addition salt" refers to those salts which retain the biological effectiveness and properties of the free bases, which are not biologically or otherwise undesirable, and which are formed with inorganic acids such as hydrochloric acid, hydrobromic acid, sulfuric acid, nitric acid, phosphoric acid and the like, and organic acids such as acetic acid, propionic acid, pyruvic acid, maleic acid, malonic acid, succinic acid, fumaric acid, tartaric acid, citric acid, benzoic acid, mandelic acid, methanesulfonic acid, ethanesulfonic acid, p-toluenesulfonic acid, salicylic acid, and the like. Particularly preferred salts of compounds of the invention are the monochloride salts and the dichloride salts.
"Pharmaceutically acceptable base addition salt" refers to those salts which retain the biological effectiveness and properties of the free acids, which are not biologically or otherwise undesirable. These salts are prepared from addition of an inorganic base or an organic base to the free acid. Salts derived from inorganic bases include, but are not limited to, the sodium, potassium, lithium, ammonium, calcium, magnesium, zinc, aluminum salts and the like. Preferred inorganic salts are the ammonium, sodium, potassium, calcium, and magnesium salts. Salts derived from organic bases include, but are not limited to, salts of primary, secondary, and tertiary amines, substituted amines including naturally occurring substituted amines, cyclic amines and basic ion exchange resins, such as isopropylamine,
trimethylamine, diethylamine, triethylamine, tripropylamine, ethanolamine, 2-dimethylaminoethanol, 2-diethylaminoethanol, trimethamine, dicyclohexylamine, lysine, arginine, histidine, caffeine, procaine, hydrabamine, choline, betaine, ethylenediamine, glucosamine, methylglucamine, theobromine, purines, piperazine, piperidine, /V-ethylpiperidine, polyamine resins and the like. Particularly preferred organic bases are isopropylamine, diethylamine, ethanolamine, trimethylamine, dicyclohexylamine, choline and caffeine.
"Ureido" refers to a radical of the formula -N(H)-C(0)-NH2.
It is understood from the above definitions and examples that for radicals containing a substituted alkyl group any substitution thereon can occur on any carbon of the alkyl group.
The compounds of the invention, or their pharmaceutically acceptable salts, may have asymmetric carbon atoms in their structure. The compounds of the invention and their pharmaceutically acceptable salts may therefore exist as single enantiomers, diastereoisomers, racemates, and mixtures of enantiomers and diastereomers. All such single enantiomers, diastereoisomers, racemates and mixtures thereof are intended to be within the scope of this invention. Absolute configuration of certain carbon atoms within the compounds, if known, are indicated by the appropriate absolute descriptor ft or S.
Utility and Administration The compounds of the invention as described herein are antagonists to the chemokine receptor known as CCR1 and have the ability to pass the blood-brain barrier. The compounds are therefore suited as in vivo diagnostic agents for imaging of Alzheimer's disease. The detection of radioactivity is performed according to well-known procedures in the art, either by using a gamma camera or by positron emission tomography (PET).
Preferably, the free base or a pharmaceutically acceptable salt form, e.g. a monochloride or dichloride salt, of a compound of the invention used in a galenical formulation as diagnostic agent. The galenical formulation containing the compound of the invention optionally contains adjuvants known in the art, e.g. buffers, sodium chloride, lactic acid, surfactants etc. A sterilization by filtration of the galenical formulation under
sterile conditions prior to usage is possible.
The radioactive dose should be in the range of 1 to 100 mCi, preferably 5 to 30 mCi, and most preferably 5 to 20 mCi per application.
Testing
The suitability of the compounds as imaging agents for Alzheimer's disease can be demonstrated by experimental protocols known to those of ordinary skill in the art. For example, the upregulation of CCR1 receptors in Alzheimer's disease brains can be demonstrated in immunohistochemical staining experiments of autopsy brain tissue collected from Alzheimer's disease patients as described in detail below in the Examples. The ability of the compounds of the invention to bind to the CCR1 receptor and their ability to pass through the blood-brain barrier, can also be assessed in known in vitro and in vivo assays as described below in the Examples. In particular, Example 10 describes a large study that was undertaken to address the degree of CCR1 expression in different stages of Alzheimer's disease. Brain tissue from 50 autopsy cases showed a correlation between degree of clinical severity (dementia) in Alzheimer's disease and CCR1 expression in dystrophic neurites. CCR1 expression in plaque-like structures within the brains of clinically normal individuals is rare. Also, CCR1 expression is not found in the brains of individuals with other neurodegenerative diseases unless there is a concomitant Alzheimer's disease pathology (specifically, Aβ1"42 in plaques).
Preferred Embodiments
Of the various aspects of the invention, certain compounds of formula (I) are preferred. In particular, compounds of formula (I) wherein X1 is a chloro at the 4-position of the phenyl ring and X2 is a 18F atom at the 4-position of the phenyl ring are preferred. Especially preferred are such compounds for use as diagnostic agents in positron emission tomography (PET).
Even more preferred are those compounds of formula (I) wherein R3 is in the 2- position of the phenyl ring and R1 is a methyl at the 2-position of the piperazinyl ring and R2 is a methyl at the 5-position of the piperazinyl ring. Equally preferred are those
compounds of formula (I) wherein R3 is in the 2-position of the phenyl ring and R1 is a methyl in the 2-position of the piperazinyl ring and R2 is hydrogen.
Further preferred are these preferred compounds in their mono- or dichloride salt form. Of the various aspects of the invention, certain compounds of formula (II) are preferred. In particular, compounds of formula (II) wherein -N(R4)R5 is in the 2-position of the phenyl ring and R1 is in the 2-position of the piperazinyl ring and R2 is in the 5-position of the piperazinyl ring. Equally preferred are those compounds of formula (II) wherein -N(R4)R 5 is in the 2-position of the phenyl ring and R1 is a methyl in the 2-position of the piperazinyl ring and R2 is hydrogen.
Even more preferred are those compounds of formula (II) wherein R5 comprises a chelator according to formula (III):
or formula (IV):
as well as their complexes with 99mTc, 186Re and 188Re. Of these preferred compounds, even more preferred are those compounds of formula (II) wherein R5 comprises a chelator according to formula (III) or (IV), and wherein the chelator is bound to the nitrogen in the
-N(R4)R5 group of the non-radioactive compound of formula (II) via a linker moiety comprising an alkyl radical having one to ten carbon atoms, wherein the alkyl radical optionally contains one to ten -C(0)-groups, one to ten -C(0)N(R)- groups, one to ten -N(R)C(0)- groups, one to ten -N(R)- groups, one to ten -N(R)2 groups, one to ten hydroxy groups, one to ten -C(0)OR-
groups, one to ten oxygen atoms, one to ten sulfur atoms, one to ten nitrogen atoms, one to ten halogen atoms, one to ten aryl groups, and one to ten saturated or unsaturated heterocyclic rings wherein R is hydrogen or alkyl. A preferred linker moiety is -C(0)-CH2- N(H)-. Of the compounds of the invention, the most preferred compounds of formula (I) are those compounds selected from the group consisting of the following: 1-(5-chloro-2-{2-[(2/:?)-4-(4-fluoro-18F-benzyl)-2-methylpiperazin-1-yl]-2- oxoethoxy}phenyl)urea; Λ/'-(mercaptoeth-1-yl)-Λ/'-(5-mercapto-3-aza-2-oxopent-1-yl)-Λ/-{5-chloro-2-[2-[4-(4- fluorobenzyl)-2-(2/:?)-methylpiperazin-1 -yl]-2-oxoethoxy]phen-1 -yl}glycylglycinamide, technetium-99m-complex; 1-(2-{2-[(2/=?)-4-(4-fluorobenzyl)-2-methylpiperazin-1-yl]-2-oxoethoxy}-5-iodo-123/-phenyl)urea; Λ/'-(2-mercaptoeth-1-yl)-/V'-(5-mercapto-3-aza-2-oxopent-1-yl)- -{5-chloro-2-[2-[4-(4- fluorobenzyl)-2-(2 :?)-methylpiperazin-1-yl]-2-oxoethoxy]phen-1-yl}glycinamide, technetium-99m-complex;
Λ/-(2-mercaptoeth-1-yl)-/V-(5-mercapto-3-azapent-1-yl)-Λ/-{5-chloro-2-[2-[4-(4-fluorobenzyl)-
2-(2R)-methylpiperazin-1 -yl]-2-oxoethoxy]phen-1 -yl}glycinamide, technetium-99m- complex; 2-(2-amino-4-chlorophenoxy)-1-[(2S/:?,5/:?S)-4-(4-fluoro-18F-benzyl)-2,5-dimethylpiperazin-1- yl]ethan-1-one;
2-(2-amino-4-chlorophenoxy)-1-[(2/:?S,5 :?S)-4-(4-fluoro-18F-benzyl)-2,5-dimethylpiperazin-1- yl]ethan-1-one; 2-(2-amino-4-chlorophenoxy)-1-[(2S ?,5S/:?)-4-(4-fluoro-18F-benzyl)-2,5-dimethylpiperazin-1- yl]ethan-1-one; 2-(2-amino-4-chIorophenoxy)-1 -[(2ftS,5SR)-4-(4-fluoro-18F-benzyl)-2,5-dimethylpiperazin-1 - yl]ethan-1-one; 2-[4-chloro-2-(diethylamino)phenoxy]-1-[(2S ?,5RS)-4-(4-fluoro-18F-benzyl)-2,5- dimethylpiperazin-1 -yl]ethan-1 -one; 2-[4-chloro-2-(diethyIamino)phenoxy]-1-[(2ftS,5f?S)-4-(4-fluoro-18F-benzyl)-2,5- dimethylpiperazin-1 -yl]ethan-1 -one;
-[4-chloro-2-(diethylamino)phenoxy]-1-[(2Sf?,5Sfl)-4-(4-fluoro-18F-benzyl)-2,5- dimethylpiperazin-1 -yl]ethan-1 -one; -[4-chloro-2-(diethyIamino)phenoxy]-1-[(2 :?S,5SR)-4-(4-fluoro-18F-benzyl)-2,5- dimethylpiperazin-1 -yl]ethan-1 -one; -(5-chloro-2-{2-[(2ftS,5Sft)-4-(4-fluoro-18F-benzyl)-2,5-dimethylpiperazin-1 -yl]-2- oxoethoxy}phenyl)-3-(2,4-dichlorophenyl)urea; -(5-chloro-2-{2-[(2SR,5Sf?)-4-(4-fluoro-18F-benzyl)-2,5-dimethylpiperazin-1-yl]-2- oxoethoxy}phenyl)-3-(2,4-dichlorophenyl)urea; -(5-chloro-2-{2-[(2RS,5f?S)-4-(4-fluoro-18F-benzyl)-2,5-dimethylpiperazin-1-yl]-2- oxoethoxy}phenyl)-3-(2,4-dichlorophenyl)urea; -(5-chloro-2-{2-[(2SR,5f?S)-4-(4-fluoro-18F-benzyl)-2,5-dimethylpiperazin-1-yl]-2- oxoethoxy}phenyl)-3-(2,4-dichlorophenyl)urea; -(5-chloro-2-{2-[(2ftS,5SR)-4-(4-fluoro-18F-benzyl)-2,5-dimethyIpiperazin-1-yl]-2- oxoethoxy}phenyl)urea; -(5-chloro-2-{2-[(2S/?,5S/:?)-4-(4-fluoro-18F-benzyl)-2,5-dimethylpiperazin-1-yl]-2- oxoethoxy}phenyl)urea; -(5-chloro-2-{2-[(2RS,5RS)-4-(4-fluoro-18F-benzyl)-2,5-dimethylpiperazin-1-yl]-2- oxoethoxy}phenyl)urea; -(5-chloro-2-{2-[(2Sft,5 :?S)-4-(4-fluoro-18F-benzyl)-2,5-dimethylpiperazin-1-yl]-2- oxoethoxy}phenyl)urea; -(5-chloro-2-{2-[(2f?S,5Sfl)-4-(4-fluoro-18F-benzyl)-2,5-dimethylpiperazin-1-yl]-2- oxoethoxy}phenyl)urea; -(5-chloro-2-{2-[(2Sft,5Sff)-4-(4-fluoro-18F-benzyl)-2,5-dimethylpiperazin-1-yl]-2- oxoethoxy}phenyl)urea; -(5-chloro-2-{2-[(2ffS,5HS)-4-(4-fluoro-18F-benzyl)-2,5-dimethylpiperazin-1 -yl]-2- oxoethoxy}phenyl)urea; -(5-chloro-2-{2-[(2Sff,5RS)-4-(4-fluoro-18F-benzyl)-2,5-dimethylpiperazin-1-yl]-2- oxoethoxy}phenyl)urea; -[(2S/?,5f?S)-4-(4-fluoro-18F-benzyl)-2,5,-dimethylpiperazin-1-yl]-2-(2-isopentylamino-4- chlorophenoxy)ethan-1 -one;
1-[(2ftS,5/:?S)-4-(4-fluoro-18F-benzyl)-2,5,-dimethylpiperazin-1-yl]-2-(2-isopentylamino-4- chlorophenoxy)ethan-1 -one; 1-[(2Sft,5S/:?)-4-(4-fluoro-18F-benzyl)-2,5,-dimethylpiperazin-1-yl]-2-(2-isopentylamino-4- chlorophenoxy)ethan-1 -one; 1 -[(2flS,5Sft)-4-(4-fluoro-18F-benzyl)-2,5,-dimethylpiperazin-1 -yl]-2-(2-isopentylamino-4- chlorophenoxy)ethan-1 -one; Λ/-(5-chloro-2-{2-[(2SR,5ftS)-4-(4-fluoro-18F-benzyl)-2,5-dimethylpiperazin-1-yl]-2- oxoethoxy}phenyl)-2-methylpropanamide; Λ/-(5-chloro-2-{2-[(2RS,5RS)-4-(4-fluoro-18F-benzyl)-2,5-dimethylpiperazin-1-yl]-2- oxoethoxy}pheny!)-2-methylpropanamide;
Λ/-(5-chloro-2-{2-[(2Sf?,5SR)-4-(4-fluoro-18F-benzyl)-2,5-dimethylpiperazin-1-yl]-2- oxoethoxy}phenyl)-2-methylpropanamide; /V-(5-chloro-2-{2-[(2RS,5Sfl)-4-(4-fluoro-18F-benzyl)-2,5-dimethylpiperazin-1-yl]-2- oxoethoxy}phenyl)-2-methylpropanamide; Λ/-(5-chloro-2-{2-[(2SR,5ftS)-4-(4-fluoro-18F-benzyl)-2,5-dimethylpiperazin-1 -yl]-2- oxoethoxy}phenyl)-2-(methoxy)acetamide; Λ/-(5-chloro-2-{2-[(2f?S,5f?S)-4-(4-fluoro-18F-benzyl)-2,5-dimethylpiperazin-1-yl]-2- oxoethoxy}phenyl)-2-(methoxy)acetamide; Λ/-(5-chloro-2-{2-[(2Sft,5Sft)-4-(4-fluoro-18F-benzyl)-2,5-dimethylpiperazin-1-yl]-2- oxoethoxy}phenyl)-2-(methoxy)acetamide;
Λ/-(5-chloro-2-{2-[(2HS,5Sft)-4-(4-fluoro-18F-benzyl)-2,5-dimethylpiperazin-1-yl]-2- oxoethoxy}phenyl)-2-(methoxy)acetamide; (£)-Λ/-(5-chloro-2-{2-[(2f?S,5Sf?)-4-(4-fluoro-18F-benzyl)-2,5-dimethylpiperazin-1-yl]-2- oxoethoxy}phenyl)-2-butenamide; (F)-Λ/-(5-chloro-2-{2-[(2Sf?,5Sft)-4-(4-fluoro-18F-benzyl)-2,5-dimethylpiperazin-1-yl]-2- oxoethoxy}phenyl)-2-butenamide; (£)-Λ/-(5-chloro-2-{2-[(2ftS,5HS)-4-(4-fluoro-18F-benzyl)-2,5-dimethyIpiperazin-1-yl]-2- oxoethoxy}phenyl)-2-butenamide; (£)-Λ/-(5-chloro-2-{2-[(2SH,5 ?S)-4-(4-fluoro-18F-benzyl)-2,5-dimethyIpiperazin-1-yl]-2- oxoethoxy}phenyl)-2-butenamide;
methyl Λ/-(5-chloro-2-{2-[(2SR,5RS)-4-(4-fluoro-18F-benzyl)-2,5-dimethylpiperazin-1-yl]-2- oxoethoxy}phenyl)succinamate; methyl Λ/-(5-chloro-2-{2-[(2f?S,5RS)-4-(4-fluoro-18F-benzyl)-2,5-dimethylpiperazin-1-yl]-2- oxoethoxy}phenyl)succinamate; methyl Λ/-(5-chloro-2-{2-[(2SR,5Sft)-4-(4-fluoro-18F-benzyl)-2,5-dimethylpiperazin-1 -yl]-2- oxoethoxy}phenyl)succinamate; methyl Λ/-(5-chloro-2-{2-[(2RS,5Sft)-4-(4-fluoro-18F-benzyl)-2,5-dimethylpiperazin-1-yl]-2- oxoethoxy}phenyl)succinamate; ethyl Λ/-(5-chloro-2-{2-[(2SR,5HS)-4-(4-fluoro-18F-benzyl)-2,5-dimethylpiperazin-1-yl]-2- oxoethoxy}phenyl)succinamate; ethyl Λ/-(5-chloro-2-{2-[(2/:?S,5f?S)-4-(4-fluoro-18F-benzyl)-2,5-dimethylpiperazin-1-yl]-2- oxoethoxy}phenyl)succinamate; ethyl Λ/-(5-chloro-2-{2-[(2S/=?,5SR)-4-(4-fluoro-18F-benzyl)-2,5-dimethylpiperazin-1-yl]-2- oxoethoxy}phenyl)succinamate; ethyl Λ/-(5-chloro-2-{2-[(2f?S,5SR)-4-(4-fluoro-18F-benzyl)-2,5-dimethylpiperazin-1 -yl]-2- oxoethoxy}phenyl)succinamate; Λ/-(5-chloro-2-{2-[(2Sf?,5flS)-4-(4-fluoro-18F-benzyI)-2,5-dimethyIpiperazin-1-yl]-2- oxoethoxy}phenyl)acetamide; Λ/-(5-chloro-2-{2-[(2f?S,5RS)-4-(4-fluoro-18F-benzyl)-2,5-dimethylpiperazin-1-yl]-2- oxoethoxy}phenyl)acetamide;
Λ/-(5-chloro-2-{2-[(2SR,5SR)-4-(4-fluoro-18F-benzyl)-2,5-dimethylpiperazin-1-yl]-2- oxoethoxy}phenyl)acetamide; Λ/-(5-chloro-2-{2-[(2RS,5Sf?)-4-(4-fluoro-18F-benzyl)-2,5-dimethylpiperazin-1-yl]-2- oxoethoxy}phenyl)acetamide; Λ/-(5-chloro-2-{2-[(2S/:?,5/:?S)-4-(4-fluoro-18F-benzyl)-2,5-dimethylpiperazin-1-yl]-2- oxoethoxy}phenyl)propanamide; Λ/-(5-chloro-2-{2-[(2ffS,5RS)-4-(4-fluoro-18F-benzyl)-2,5-dimethylpiperazin-1-yl]-2- oxoethoxy}phenyl)propanamide; Λ/-(5-chloro-2-{2-[(2Sf?,5SR)-4-(4-fluoro-18F-benzyl)-2,5-dimethylpiperazin-1-yl]-2- oxoethoxy}phenyl)propanamide;
Λ/-(5-chloro-2-{2-[(2RS,5Sf?)-4-(4-fluoro-18F-benzyl)-2,5-dimethylpiperazin-1-yl]-2- oxoethoxy}phenyl)propanamide; Λ/-(5-chloro-2-{2-[(2SR,5HS)-4-(4-fluoro-18F-benzyl)-2,5-dimethylpiperazin-1-yl]-2- oxoethoxy}phenyl)-3-fluorobenzamide; Λ/-(5-chloro-2-{2-[(2f?S,5/:?S)-4-(4-fluoro-18F-benzyl)-2,5-dimethylpiperazin-1-yl]-2- oxoethoxy}phenyl)-3-fluorobenzamide; Λ/-(5-chloro-2-{2-[(2SR,5SR)-4-(4-fiuoro-18F-benzyl)-2,5-dimethylpiperazin-1-yl]-2- oxoethoxy}phenyl)-3-fluorobenzamide; Λ/-(5-chloro-2-{2-[(2f?S,5Sf?)-4-(4-fluoro-18F-benzyl)-2,5-dimethylpiperazin-1-yl]-2- oxoethoxy}phenyl)-3-fluorobenzamide;
1-(5-chloro-2-{2-[(2SR,5f?S)-4-(4-fluoro-18F-benzyI)-2,5-dimethylpiperazin-1-yl]-2- oxoethoxy}phenyl)-3-(p-tolyl)urea; 1-(5-chloro-2-{2-[(2/:?S,5f?S)-4-(4-fluoro-18F-benzyl)-2,5-dimethylpiperazin-1-yl3-2- oxoethoxy}phenyl)-3-(p-tolyI)urea; 1 -(5-chloro-2-{2-[(2SR,5Sff)-4-(4-fluoro-18F-benzyl)-2,5-dimethylpiperazin-1 -yl]-2- oxoethoxy}phenyl)-3-(p-tolyl)urea; 1-(5-chloro-2-{2-[(2 :?S,5SR)-4-(4-fluoro-18F-benzyl)-2,5-dimethylpiperazin-1-yl]-2- oxoethoxy}phenyl)-3-(p-tolyl)urea; 1-(5-chloro-2-{2-[(2RS,5Sft)-4-(4-fluoro-18F-benzyl)-2,5-dimethylpiperazin-1-yl]-2- oxoethoxy}phenyl)-3-ethylurea;
1-(5-chloro-2-{2-[(2Sft,5Sfl)-4-(4-fluoro-18F-benzyl)-2,5-dimethylpiperazin-1-yl]-2- oxoethoxy}phenyl)-3-ethylurea; 1-(5-chloro-2-{2-[(2RS,5f?S)-4-(4-fluoro-18F-benzyl)-2,5-dimethylpiperazin-1-yl]-2- oxoethoxy}phenyl)-3-ethylurea; 1 -(5-chloro-2-{2-[(2Sf?,5f?S)-4-(4-fluoro-18F-benzyl)-2,5-dimethylpiperazin-1 -yl]-2- oxoethoxy}phenyl)-3-ethylurea; 1-benzyl-3-(5-chloro-2-{2-[(2S ?,5/:?S)-4-(4-fluoro-18F-benzyl)-2,5-dimethylpiperazin-1-yl]-2- oxoethoxy}phenyl)urea; 1-benzyl-3-(5-chloro-2-{2-[(2RS,5RS)-4-(4-fluoro-18F-benzyl)-2,5-dimethylpiperazin-1-yI]-2- oxoethoxy}phenyl)urea;
1-benzyl-3-(5-chloro-2-{2-[(2SR,5Sf?)-4-(4-fluoro-18F-benzyl)-2,5-dimethylpiperazin-1-yl]-2- oxoethoxy}phenyl)urea; 1-benzyI-3-(5-chloro-2-{2-[(2RS,5Sfl)-4-(4-fluoro-18F-benzyl)-2,5-dimethylpiperazin-1-yl]-2- oxoethoxy}phenyl)urea; 1 -(5-chloro-2-{2-[(2f?S,5S :?)-4-(4-fluoro-18F-benzyl)-2,5-dimethylpiperazin-1 -yl]-2- oxoethoxy}phenyl)-3-(4-nitrophenyl)urea; 1-(5-chloro-2-{2-[(2SR,5Sft)-4-(4-fluoro-18F-benzyl)-2,5-dimethylpiperazin-1-yl]-2- oxoethoxy}phenyl)-3-(4-nitrophenyl)urea; 1-(5-chloro-2-{2-[(2RS,5RS)-4-(4-fluoro-18F-benzyl)-2,5-dimethylpiperazin-1-yl]-2- oxoethoxy}phenyl)-3-(4-nitrophenyl)urea;
1-(5-chloro-2-{2-[(2Sf?,5ftS)-4-(4-fluoro-18F-benzyl)-2,5-dimethylpiperazin-1-yl]-2- oxoethoxy}phenyl)-3-(4-nitrophenyl)urea; 2-(2-benzylamino-4-chlorophenoxy)-1-[(2SR,5RS)-4-(4-fluoro-18F-benzyl)-2,5- dimethylpiperazin-1 -yl]ethan-1 -one; 2-(2-benzylamino-4-chlorophenoxy)-1-[(2/:?S,5f?S)-4-(4-fluoro-18F-benzyl)-2,5- dimethylpiperazin-1 -yl]ethan-1 -one; 2-(2-benzylamino-4-chlorophenoxy)-1-[(2Sft,5Sft)-4-(4-fluoro-18F-benzyl)-2,5- dimethylpiperazin-1 -yl]ethan-1 -one; 2-(2-benzylamino-4-chlorophenoxy)-1-[(2RS,5SR)-4-(4-fluoro-18F-benzyl)-2,5- dimethylpiperazin-1 -yl]ethan-1 -one;
/V-(5-chloro-2-{2-[(2f?S,5Sft)-4-(4-fluoro-18F-benzyl)-2,5-dimethylpiperazin-1-yl]-2- oxoethoxy}phenyl)glycinamide; Λ-(5-chloro-2-{2-[(2SR,5ftS)-4-(4-fluoro-18F-benzyl)-2,5-dimethylpiperazin-1-yl]-2- oxoethoxy}phenyl)glycinamide; Λ/-(5-chloro-2-{2-[(2SH,5SR)-4-(4-fluoro-18F-benzyl)-2,5-dimethylpiperazin-1-yl]-2- oxoethoxy}phenyI)glycinamide; /V-(5-chloro-2-{2-[(2f?S,5ftS)-4-(4-fluoro-18F-benzyl)-2,5-dimethylpiperazin-1-yl]-2- oxoethoxy}phenyl)glycinamide; 1-(5-chloro-2-{2-[(2ff)-4-(4-fluoro-18F-benzyl)-2-methylpiperazin-1-yI]-2- oxoethoxy}phenyl)urea;
1-(5-chloro-2-{2-[(2S)-4-(4-fluoro-18F-benzyl)-2-methylpiperazin-1-yl]-2- oxoethoxy}phenyl)urea; Λ/-(5-chloro-2-{2-[(2f?S,5SR)-4-(4-fluoro-18F-benzyl)-2,5-dimethyl-piperazin-1-yl]-2- oxoethoxy}phenyl)-2-(methylamino)acetamide; Λ/-(5-chloro-2-{2-[(2Sf?,5Sf?)-4-(4-fluoro-18F-benzyl)-2,5-dimethyl-piperazin-1-yl]-2- oxoethoxy}phenyl)-2-(methylamino)acetamide; Λ/-(5-chloro-2-{2-[(2RS,5ffS)-4-(4-fluoro-18F-benzyl)-2,5-dimethyl-piperazin-1-yl]-2- oxoethoxy}phenyl)-2-(methylamino)acetamide; Λ/-(5-chloro-2-{2-[(2S ?,5ftS)-4-(4-fluoro-18F-benzyl)-2,5-dimethyl-piperazin-1-yl]-2- oxoethoxy}phenyl)-2-(methylamino)acetamide;
2-bromo-Λ/-(5-chloro-2-{(2S/:?)5f?S)-4-(4-fluoro-18F-benzyl)-2,5-dimethylpiperazin-1-yl]-2- oxoethoxy}phenyl)acetamide; 2-bromo-/V-(5-chloro-2-{(2f?S,5ftS)-4-(4-fluoro-18F-benzyl)-2,5-dimethylpiperazin-1-yl]-2- oxoethoxy}phenyl)acetamide; 2-bromo-Λ/-(5-chloro-2-{(2Sft,5Sf?)-4-(4-fluoro-18F-benzyl)-2,5-dimethylpiperazin-1 -yl]-2- oxoethoxy}phenyl)acetamide; 2-bromo-/V-(5-chloro-2-{(2RS,5S/:f)-4-(4-fluoro-18F-benzyl)-2,5-dimethylpiperazin-1-yl]-2- oxoethoxy}phenyl)acetamide; Λ/-(5-chloro-2-{2-[(2RS,5Sf?)-4-(4-fluoro-18F-benzyl)-2,5-dimethylpiperazin-1-yl]-2- oxoethoxy}phenyl)-2-(ureido)acetamide;
Λ/-(5-chloro-2-{2-[(2SR,5Sft)-4-(4-fluoro-18F-benzyl)-2,5-dimethylpiperazin-1-yl]-2- oxoethoxy}phenyl)-2-(ureido)acetamide; Λ/-(5-chloro-2-{2-[(2RS,5ftS)-4-(4-fluoro-18F-benzyl)-2,5-dimethylpiperazin-1-yl]-2- oxoethoxy}phenyl)-2-(ureido)acetamide; Λ/-(5-chloro-2-{2-[(2SR,5RS)-4-(4-fluoro-18F-benzyl)-2,5-dimethylpiperazin-1-yl]-2- oxoethoxy}phenyl)-2-(ureido)acetamide; Λ/-(5-chloro-2-{2-[(2ftS,5S ?)-4-(4-fluoro-'l8F-benzyl)-2,5-dimethyIpiperazin-1-yl]-2- oxoethoxy}phenyl)-2-(1-methylureido)acetamide; Λ/-(5-chloro-2-{2-[(2Sft,5Sft)-4-(4-fluoro-18F-benzyl)-2,5-dimethylpiperazin-1-yl]-2- oxoethoxy}phenyl)-2-(1 -methylureido)acetamide;
Λ/-(5-chloro-2-{2-[(2HS,5RS)-4-(4-fluoro-18F-benzyl)-2,5-dimethylpiperazin-1-yl]-2- oxoethoxy}phenyl)-2-(1-methylureido)acetamide; Λ/-(5-chloro-2-{2-[(2Sft,5f?S)-4-(4-fluoro-18F-benzyl)-2,5-dimethylpiperazin-1-yl]-2- oxoethoxy}phenyl)-2-(1-methylureido)acetamide; (2ftS)-Λ/-(5-chloro-2-{2-[(2f?S,5SR)-4-(4-fluoro-18F-benzyl)-2,5-dimethylpiperazin-1-yl]-2- oxoethoxy}phenyl)-2-aminopropanamide; (2Sf?)-Λ/-(5-chloro-2-{2-[(2RS,5SR)-4-(4-fluoro-18F-benzyl)-2,5-dimethylpiperazin-1-yl]-2- oxoethoxy}phenyl)-2-aminopropanamide; (2RS)-Λ/-(5-chloro-2-{2-[(2Sft,5SR)-4-(4-fluoro-18F-benzyl)-2,5-dimethylpiperazin-1-yl]-2- oxoethoxy}phenyl)-2-aminopropanamide;
(2SR)-Λ/-(5-chloro-2-{2-[(2SR,5SR)-4-(4-fluoro-18F-benzyl)-2,5-dimethylpiperazin-1-yl]-2- oxoethoxy}phenyl)-2-aminopropanamide; (2 ?S)-Λ-(5-chloro-2-{2-[(2f?S,5f?S)-4-(4-fluoro-18F-benzyl)-2,5-dimethylpiperazin-1-yl]-2- oxoethoxy}phenyl)-2-aminopropanamide; (2SR)-Λ/-(5-chloro-2-{2-[(2RS,5RS)-4-(4-fluoro-18F-benzyl)-2,5-dimethylpiperazin-1 -yl]-2- oxoethoxy}phenyl)-2-aminopropanamide; (2f?S)-Λ/-(5-chloro-2-{2-[(2SR,5RS)-4-(4-fluoro-18F-benzyl)-2,5-dimethylpiperazin-1-yl]-2- oxoethoxy}phenyl)-2-aminopropanamide; (2S/?)-Λ/-(5-chloro-2-{2-[(2Sft,5f?S)-4-(4-fluoro-18F-benzyl)-2,5-dimethyIpiperazin-1-yl]-2- oxoethoxy}phenyl)-2-aminopropanamide;
Λ/-(5-chloro-2-{2-[(2SR,5RS)-4-(4-fluoro-18F-benzyl)-2,5-dimethylpiperazin-1-yl]-2- oxoethoxy}phenyl)-2-(2,4-difluorobenzoylamino)acetamide; Λ/-(5-chloro-2-{2-[(2/:?S,5/:?S)-4-(4-fluoro-18F-benzyl)-2,5-dimethylpiperazin-1-yl]-2- oxoethoxy}phenyl)-2-(2,4-difluorobenzoylamino)acetamide; Λ/-(5-chloro-2-{2-[(2S/:?,5SR)-4-(4-fluoro-18F-benzyl)-2,5-dimethylpiperazin-1-yl]-2- oxoethoxy}phenyl)-2-(2,4-difluorobenzoylamino)acetamide; A/-(5-chloro-2-{2-[(2f?S,5SR)-4-(4-fluoro-18F-benzyl)-2,5-dimethylpiperazin-1-yl]-2- oxoethoxy}phenyl)-2-(2,4-difluorobenzoylamino)acetamide; Λ/-(5-chloro-2-{2-[(2Sft,5RS)-4-(4-fluoro-18F-benzyl)-2,5-dimethylpiperazin-1-yl]-2- oxoethoxy}phenyl)-2-(methoxyacetylamino)acetamide;
Λ/-(5-chloro-2-{2-[(2RS,5RS)-4-(4-fluoro-18F-benzyl)-2,5-dimethylpiperazin-1-yl]-2- oxoethoxy}phenyl)-2-(methoxyacetylamino)acetamide; Λ/-(5-chloro-2-{2-[(2S ?,5SR)-4-(4-fluoro-18F-benzyl)-2,5-dimethylpiperazin-1-yl]-2- oxoethoxy}phenyl)-2-(methoxyacetylamino)acetamide; Λ/-(5-chloro-2-{2-[(2f?S,5S/:?)-4-(4-fluoro-18F-benzyl)-2,5-dimethylpiperazin-1-yl]-2- oxoethoxy}phenyl)-2-(methoxyacetylamino)acetamide; Λ/-(5-chloro-2-{2-[(2SR,5ftS)-4-(4-fluoro-18F-benzyl)-2,5-dimethylpiperazin-1-yl]-2- oxoethoxy}phenyl)-2-(2-iodobenzoylamino)acetamide; Λ/-(5-chloro-2-{2-[(2 ?S,5flS)-4-(4-fluoro-18F-benzyl)-2,5-dimethylpiperazin-1-yl]-2- oxoethoxy}phenyl)-2-(2-iodobenzoylamino)acetamide;
Λ/-(5-chloro-2-{2-[(2Sf?,5S/:?)-4-(4-fluoro-18F-benzyl)-2,5-dimethylpiperazin-1-yl]-2- oxoethoxy}phenyl)-2-(2-iodobenzoylamino)acetamide; Λ/-(5-chloro-2-{2-[(2RS,5SR)-4-(4-fluoro-18F-benzyl)-2,5-dimethylpiperazin-1-yl]-2- oxoethoxy}phenyl)-2-(2-iodobenzoylamino)acetamide; Λ/-(5-chloro-2-{2-[(2/:?)-4-(4-fluoro-18F-benzyl)-2-methylpiperazin-1 -yl]-2- oxoethoxy}phenyl)glycinamide; and Λ/-(5-chloro-2-{2-[(2S)-4-(4-fluoro-18F-benzyl)-2-methylpiperazin-1-yl]-2- oxoethoxy}phenyl)glycinamide; as well as the mono- and dichloride salts thereof.
Preparation of the Compounds of the Invention A. Preparation of Compounds of Formula (I)
In general, the radioactive imaging agents of formula (I ) of the present invention are prepared by reacting radioactive 4-halobenzyl derivatives with piperazine derivatives. Preferred are 18F-labeled 4-fluorobenzyl derivatives for PET-imaging. A general method for the preparation of 4-fluoro-18F-benzyl halides is described in Iwata etal., Applied Radiation and Isotopes (2000), Vol. 52, pp. 87-92.
The 18F-labeled 4-fluorobenzyl derivatives are prepared by reaction of a benzaldehyde compound of formula (a) with 18F" ions to obtain a benzaldehyde compound of formula (b):
wherein LG is a leaving group, for example, bromo, chloro, iodo, nitro, or N(R)3 + X" (where R is alkyl and X is a halo ion, such as Br", Cl", or I"; an ion of a alkanoic acid, such as an acetate ion (CH3C(0)0 ); or an ion of an alkylsulfonic acid or haloalkylsulfonic acid, such as triflat (CF3SO3 ")). Preferably LG is triflat. Starting from the compound of formula (b), several synthetic pathways are possible in preparing the compounds of formula (I).
In a first synthetic pathway, a compound of formula (b) is reduced with NaBH4 to obtain a compound of formula (c):
The compound of formula (c) is then reacted with HI, P2I4 or Ph3PBr2 to obtain an iodo- or bromo-substituted compound of formulae (d) or (e):
The compounds of formulae (d) and (e) can be obtained with a radiochemical yield of 50 to 60%. The radiochemical purity is greater than 95%. The specific activity of the compounds is 5 mCi per 1 nmol. A compound of formulae (d) or (e) can then be reacted with a piperazine derivative (f) to obtain a compound of formula (g) (a compound of formula (I)):
(f) (d) or (e)
Compounds of formula (f) may be prepared according to methods known to those of ordinary skill in the art and is described in detail in PCT Published Patent Application, WO 98/56771. In a second synthetic pathway, a compound of formula (b) is directly reacted with a compound of formula (f) using a reducing agent, for example, formic acid, ammonium formiate, NaBH4, or NaBH3CN, to obtain a compound of formula (g) (a compound of formula (I)):
B. Preparation of Compounds of Formula (II)
For Single Photon Emission Computed Tomography ("SPECT"), 99mTc-labeled compounds are preferred. Those compounds are compounds of formula (II). A general synthetic pathway for these compounds starts with non-radioactive analogues of compounds of formula (II) that are reacted with 99mTc-binding chelators, e.g. N2S2-Chelators. Preparation of the non-radioactive analogs of the compounds of formula (II) is described in detail in PCT Published Patent Application, WO 98/56771. The synthesis of the chelators follows standard procedures, for example, the procedures described in A. Mahmood et al., A N2S2-
Tetradentate Chelate for Solid-Phase Synthesis: Technetium, Rhenium in Chemistry and Nuclear Medicine (1999), Vol. 5, p. 71 , or in Z.P. Zhuang etal., Bioconjugate Chemistry (1999), Vol. 10, p. 159.
Preferred chelators are chelators of formulae (III) or (IV):
One of the chelators is either bound directly to the nitrogen in the -N(R4)R5 group of the non-radioactive compound of formula (II), or via a linker moiety comprising an alkyl radical having one to ten carbon atoms, wherein the alkyl radical optionally contains one to ten -C(0)-groups, one to ten -C(0)N(R)- groups, one to ten -N(R)C(0)- groups, one to ten -N(R)- groups, one to ten -N(R)2 groups, one to ten hydroxy groups, one to ten -C(0)OR- groups, one to ten oxygen atoms, one to ten sulfur atoms, one to ten nitrogen atoms, one to ten halogen atoms, one to ten aryl groups, and one to ten saturated or unsaturated heterocyclic rings wherein R is hydrogen or alkyl. A preferred linker moiety is -C(0)-CH2- N(H)-.
The following specific examples are provided as a guide to assist in the practice of the invention, and are not intended as a limitation on the scope of the invention.
Example 1 Preparation of 1-(5-Chloro-2-{2-[(2β)-2-methylpiperazin-1-yl]-2- oxoethoxy}phenyl)urea
MeClc DIEA, MeCI2 a
A. DIEA (19.10 mL, 110 mmol) was added to a solution of (R)-(-)-2- methylpiperazine (10 g, 100 mmol) in 250 mL of methylene chloride. The solution was cooled to -10°C. The BOC anhydride was dissolved in 250 mL of methylene chloride and this solution was added to the chilled piperazine solution over 1 hour. The reaction was allowed to warm to ambient temperature over 16 hours. The reaction mixture was filtered to remove the solids and the filtrate washed with 500 mL of water, dried over magnesium sulfate, filtered and evaporated to an oil. The oil was purified by flash column chromatography to afford 11.0 g of the compound of formula (a).
B. The compound of formula (a) (11.0 g, 55 mmol) and DIEA (10.5 mL, 60.4 mmol) were dissolved in 100 mL of methylene chloride. The resulting solution was chilled to -10°C. Chloroacetyl chloride (4.37 mL, 55 mmol) was added dropwise to the solution maintaining the temperature at -10°C. After stirring for 1 hour the reaction mixture was washed with 100 mL of water, dried over magnesium sulfate, filtered and evaporated to an oil. The oil was purified by flash column chromatography to afford 14.8 g of the compound of
formula (b).
C. To a solution of the compound of formula (b) (14.8 g , 53.5 mmol) and the compound of formula (e) (9.98 g, 53.5 mmol) in 75 mL of DMSO was added potassium carbonate (18.48 g, 133J mmol). The resulting mixture was heated to 50°C for 3 hours. The mixture was cooled to 30°C and poured into 700 mL of water. The water was extracted three times with 200 mL of ethyl acetate. The ethyl acetate extracts were combined and washed with 200 mL of 1 N KOH followed by brine. The organic layer was the dried over magnesium sulfate, filtered and evaporated to a foam. The foam was purified by flash column chromatography to afford 19.6 g of the compound of formula (c). D. The compound of formula (c) (7.68 g, 18 mmol) was dissolved in 40 mL of ethyl acetate. The resulting solution was chilled in an ice bath and anhydrous HCI gas was bubbled through the solution for 5 minutes. The product precipitated while the mixture was allowed to sit at ambient temperature for 1 hour. The product was collected by filtration, washed on the filter with fresh ethyl acetate, and dried under vacuum at ambient temperature to constant weight to afford 5.9 g of 1 -(5-chloro-2-{2-[(2 :?)-2-methylpiperazin-1 -yl]-2- oxoethoxy}phenyl)urea, the compound of formula (d), as white solid; NMR (2 rotomers); (400 MHz, DMSO) 9J (m, 0.5H), 9.2 (m, 0.5H), 8.16 (s, 1H), 8.13 (s, 0.5H), 6.8 (s, 2H), 4.9 (m, 2H), 4.4 (m, 5H), 3.8 ( bs, 0.5H), 3.4, (bs, 0.5H), 3.2, (m, 2.5H), 3.0 (m, 2 H) 1.2-1.4 (m, 3H) ppm.
Example 2 Preparation of the Compound of Formula (e)
To a solution of 2-amino-4-chlorophenol (10 g, 69.7 mmol) in 100 mL of anhydrous
THF at ambient temperature was added trimethylsilyl isocyanate (18.8 mL, 139.4 mmol) in one portion. The solution was heated to 60°C and remained at this temperature for 22 hours at which time water (1.3 mL, 767 mmol) was added. After 30 minutes the solution was
cooled to ambient temperature and concentrated to a brown oil. This oil was dissolved in ethyl acetate, treated with activated carbon, dried over magnesium sulfate and filtered. The filtrate was concentrated to a pink solid which was crystallized from 10:1 , toluene/methanol to give 5.4 g of the compound of formula (e) as tan powder.
Example 3 Preparation of 1 -(5-Chloro-2-{2-[(2fl)-4-(4-f luoro-18 -benzyl)-2-methylpiperazin-1 -yl]-2- oxoethoxy}phenyl)urea
A. Hydrogen fluoride-18F was prepared in a cyclotron by bombardment of H20-180 with protons. The resulting hydrogen fluoride-18F was adsorbed on an anion- exchange cartridge. The hydrogen fluoride-18Fwas eluted with a solution of Kryptofix 222 (15 mg, 40 μmol) and K2C03 (2.77 mg, 20 μmol) in aqueous acetonitrile (1.5 mL, 66%). The radioactive fractions were evaporated to dryness in a nitrogen gas stream. This procedure was repeated three times with dry acetonitrile (1 mL). After addition of a solution of 4- trimethylammonium-benzaldehyde-triflate (2 mg, 6.4 μmol) in dry DMF (250 μl) the resulting reaction mixture was heated for 5 minutes to 100°C. After cooling to ambient temperature a solution of 1-(5-chloro-2-{2-[(2R)-2-methylpiperazin-1-yl]-2-oxoethoxy}phenyl)urea, a compound of formula (d), (3 mg, 8.3 μmol) in 50 μl acetic acid and a solution of sodium- cyano-borhydride (4 mg, 63.7 μmol) in 100 μl dry DMF were added. The reaction mixture was heated to 120°C for 10 minutes. After addition of 5 mL of water the mixture was filtered over a polystyrol-cartridge. The adsorbed product was washed with 2 mL of water to afford the title compound, 1-(5-chloro-2-{2-[(2fl)-4-(4-fluoro-18F-benzyl)-2-methylpiperazin-1-yl]-2- oxoethoxy}phenyl)urea, which was eluted with 1.5 mL acetonitrile and purified by HPLC.
B. In a similar manner, other compounds of formula (I) containing a 18F atom are prepared.
Example 4 Preparation of /V-(5-Chloro-2-{2-[(2fl)-4-(4-f luorobenzyl)-2-methylpiperazin-1 -yl]-2- oxoethoxy}phenyl)glycinamide
A. To a solution of (f?)-(-)-2-methylpiperazine (2.0 g, 20 mmol) in 20 mL CH2CI2 was added DIEA (5.2 g, 40 mmol) and 4-fluorobenzyl chloride (2.39 mL, 20 mmol). The resulting mixture was stirred at ambient temperature for 15 hours. After the reaction was completed, the reaction mixture was washed with water (3X20 mL) and brine, then dried over Na2S04, filtered and concentrated in vacuo to afford the compound of formula (f) (2.2 g) as a white solid.
B. To a solution of the compound of formula (f) (2.2 g, 10 mmol) in 50 mL CH2CI2 was added chloroacetyl chloride (0.84 mL, 10 mmol). The resulting mixture was stirred at ambient temperature for 10 minutes and then triethylamine (3 mL, 21 mmol) was added. After 30 minutes, the mixture was washed with water (3x20mL) and brine, then dried over Na2S0 , filtered and concentrated in vacuo to afford an oil. Purification by flash column chromatography afforded the compound of formula (g) (2.5 g).
C. To a solution of the compound of formula (g) (2.4 g, 8.4 mmol) in 50 mL DMF was added K2C03 (2.5 g, 17 mmol), Nal (0.2 g) and 4-chloro-2-nitrophenol (1.3 g, 8.4 mmol). The resulting mixture was heated at 70-80°C. After 1 hour, the mixture was concentrated in vacuo, then taken up in ethyl acetate (150 mL) and washed with water (3X100mL)and then brine. The organic layer was separated, dried over Na2S0 , filtered and concentrated in vacuo to afford an oil. Purification by flash column chromatography afforded the compound of formula (h) (3.1 g).
D. To a solution of the compound of formula (h) (1.1 g, 2.6 mmol) in 10 mL ethanol was added a solution of tin(ll) chloride dihydrate (3.0 g, 13 mmol) in 5 mL ethanol. The resulting mixture was heated at 75°C. After 1 hour, the reaction was concentrated in vacuo, then taken in ethyl acetate (100 mL), washed with 1 N NaOH solution in water (3X1 OOmL) and brine. The organic layer was separated, dried over Na2S04) filtered and concentrated in vacuo to afford an oil. Purification by flash column chromatography afforded the compound of formula (|) (0J5g).
E. To a solution of the compound of formula (i) (0.7 g, 1.78 mmol) in 10 mL DMF was added BOC-Gly-OSU (0.58 g, 2.13 mmol). The resulting mixture was heated at 50- 60°C. After 24 hours, the mixture was concentrated in vacuo, then taken up in ethyl acetate (150 mL) and washed with water (3X1 OOmL) and then brine. The organic layer was separated, dried over Na2S0 , filtered and concentrated in vacuo to afford an oil.
Purification by flash column chromatography afforded the compound of formula Q) (0.7 g).
F. To a solution of the compound of formula Q) (0.6 g, 1.1 mmol) in 10 mL CH2CI2 was added TFA (5 mL). The resulting mixture was heated at ambient temperature. After the reaction was completed in 1 hour, the reaction was concentrated in vacuo, then taken up in ethyl acetate (100 mL), washed with 1 N NaOH solution in water (2X1 OOmL) and brine. The
organic layer was separated, dried over Na2S04, filtered and concentrated in vacuo to afford an oil. Purification by flash column chromatography afforded N-(5-c\ι\oro-2-{2-[(2R)-4-(4- fluorobenzyl)-2-methylpiperazin-1-yl]-2-oxoethoxy}phenyl)gIycinamide, the compound of formula (k), (0.45 g) as a white solid; NMR (CDCI3) 10.2 (s, 1), 8.5 (s, 1), 7.3 (m, 2), 7.0 (m, 3), 6.8 (d, 1), 4.7 (m, 2), 3.4-3.6 (m, 5), 3.0 (m, 1), 2.8 (m,1), 2.6 (d, 1), 2.2 (m, 1), 2.0 (m, 2), 1.2-1.4 (m, 3) ppm.
Example 5 Λ '-(mercaptoeth-1-yl)-Λ '-(5-mercapto-3-aza-2-oxopent-1-yl)-Λ^{5-chloro-2-[2-[4-(4- fluorobenzyl)-2-(2 ?)-methylpiperazin-1-yl]-2-oxoethoxy]phen-1-yl}glycylglycinamide,
Technetium-99m-complex
A. To a stirred solution of Λ/-{5-chloro-2-[2-[4-(4-fluorobenzyl)-2-(2/:?)- methylpiperazin-1-yl]-2-oxoethoxy]phen-1 -yl}glycinamide (175.5 mg, 0.4 mmol) (the compound of formula (k) as prepared above in Example 4), Λ/-(S-trityl-2-mercaptoeth-1-yl)- Λ/-(S-trityl-5-mercapto-3-aza-2-oxopent-1-yl)glycine (291.4 mg, 0.4 mmol) (which can be synthesized according to A. Mahmood et al., A N2S2-Tetradentate Chelate for Solid-Phase Synthesis: Technetium, Rhenium in Chemistry and Nuclear Medicine (1999), Vol. 71 ), and Λ/-hydroxysuccinimide (45.5 mg, 0.4 mmol) in 5 mL dichloromethane was added dropwise a solution of dicyclohexylcarbodiimide (81.4 mg, 0.4 mmol) in 3 mL dichloromethane. The resulting suspension was stirred over night at ambient temperature. After filtration, the resulting solution was evaporated under reduced pressure. The desired product, /V-(S-trityl-2-sulfanyleth-1-yl)-/V-(S-trityl-5-mercapto-3-aza-2-oxopent-1-yl)-A/-{5-chloro-2- [2-[4-(4-fluorobenzyl)-2-(2f?)-methylpiperazin-1-yl]-2-oxoethoxy]phen-1- yl}glycylglycinamide (340 mg, 72.8%) was isolated after silica gel chromatography (eluent: dichloromethane/methanol, 98:2) as a white powder. Elemental Analysis:
Calc: C 69.93 H 5.87 N 7.20 O 6.85 S 5.49
Found: C 69.69 H 6.05 N 7.01 O S 5.32
B. /V-(S-Trityl-2-sulfanyleth-1 -yl)-/V-(S-trityl-5-mercapto-3-aza-2-oxopent-1 -yl)-/V- {5-chloro-2-[2-[4-(4-fluorobenzyl)-2-(2ft)-methylpiperazin-1 -yl]-2-oxoethoxy]phen-1 -
yl}glycylglycinamide (116.8 mg, 0.1 mmol), as prepared above, was dissolved in 5 mL trifluoroacetic acid. After addition of triethyl silane (48 μl, 0.3 mmol) the resulting suspension was stirred for 15 minutes at ambient temperature. The titrate was evaporated under reduced pressure and the residue was triturated with 7 mL diethyl ether. The precipitate was stirred for 1 hour at ambient temperature and filtered off, yielding the desired product, Λ/'-(mercaptoeth-1-yl)-Λ/'-(5-mercapto-3-aza-2-oxopent-1-yl)-Λ/-{5-chloro-2-[2-[4-(4- fluorobenzyl)-2-(2FΪ)-methylpiperazin-1 -yl]-2-oxoethoxy]phen-1 -yljglycylglycinamide, bis- trifluoracetic acid salt (87 mg, 95.5%), as a white solid. Elemental Analysis: Calc: C 44.81 H 4.65 N 9.22 O 15.80 S 7.04
Found: C 44.54 H 4.91 N 8.99 O S 6.80
C. Disodium tartrate (1 mg) and /V-(mercaptoeth-1 -yl)-/V-(5-mercapto-3-aza-2- oxoρent-1-yl)-Λ/-{5-chloro-2-[2-[4-(4-fluorobenzyl)-2-(2f?)-methylpiperazin-1-yl]-2- oxoethoxy]phen-1-yl}glycylglycinamide, bis-trifluoracetic acid salt (100 μg), as prepared above, were dissolved in 500 μl sodium phosphate buffer (0.1 M, pH=8.5). After addition of 37MBq 99mTc-generator eluate, 5 μl tin-(ll) chloride solution was added and the mixture was heated for 10 min to 100°C. HPLC analysis showed a major peak indicating that the desired product, Λ/'-(mercaptoeth-1 -yl)-Λ/'-(5-mercapto-3-aza-2-oxopent-1 -yl)-Λ/-{5-chloro-2-[2-[4-(4- fluorobenzyl)-2-(2R)-methylpiperazin-1-yl]-2-oxoethoxy]phen-1 -yl}glycylglycinamide, Technetium-99m-complex, was synthesized with a RCP > 90%.
Example 6 Preparation of 1 -(2-{2-[(2 ?)-4-(4-Fluorobenzyl)-2-methylpiperazin-1 -yl]-2-oxoethoxy}-5- iodophenyl)urea
m
A. To a solution of p-iodophenol (2.2 g, 10 mmol) in 18 mL acetic acid was added a solution of HN03 (0J mL, 70%) in 5 mL acetic acid dropwise over 10 minutes. The resulting mixture was stirred at ambient temperature. After 30 minutes, the reaction mixture was diluted by 100 mL ice-water. The precipitate was collected, washed with 100 mL water. Purification by flash column chromatography afforded 1.2 g of 2-nitro-4-iodophenol.
B. To a solution of the compound of formula (g) (0.3 g, 1.05 mmol) (as prepared herein) in 10 mL DMF was added K2C03 (0.45 g, 3.2 mmol), Nal (0.01 g) and 2-nitro-4-
iodophenol (0.28 g, 1.05 mmol). The resulting mixture was heated at 70-80°C. After 1 hour, the mixture was concentrated in vacuo, then taken up in ethyl acetate (150 mL) and washed with water (3X100mL)and then brine. The organic layer was separated, dried over Na2S0 , filtered and concentrated in vacuo to afford an oil. Purification by flash column chromatography afforded 0.28 of the compound of formula (I).
C. To a solution of the compound of formula (I) (0.28 g, 0.55 mmol) in 5 mL ethanol was added a solution of Tin(ll) chloride dihydrate (0.616 g, 2J3 mmol) in 5 mL ethanol. The resulting mixture was heated at 75°C. After 1 hour, the reaction was concentrated in vacuo, then taken up in ethyl acetate (100 mL), washed with 1 N NaOH solution in water (3X1 OOmL) and brine. The organic layer was separated, dried over Na2S04, filtered and concentrated in vacuo to afford an oil. Purification by flash column chromatography afforded the compound of formula (m) (0.25g).
D. To a solution of the compound of formula (m) (0.25 g, 0.52 mmol) in 3 mL AcOH was added water (6 mL). The resulting mixture was stirred at ambient temperature for 10 minutes, then a solution of KOCN (0.085 g, 1.0 mmol) in 1 mL water was added dropwise. The reaction mixture was stirred at ambient temperature for 10 minutes, then heated at 55°C for 5 minutes. After the reaction was completed, the reaction mixture was concentrated in vacuo, then taken up in CH2CI2 (50 mL), washed with 2N NaOH solution in water (2x1 OOmL) and brine. The organic layer was separated, dried over Na2S04, filtered and concentrated in vacuo to afford an oil. Purification by flash column chromatography afforded the compound of formula (n) (0.16 g) as a white solid; NMR (CDCI3) 9.0 (s, 1), 8.6 (s, 1), 7.3 (m, 2), 7.0 (t, 3), 6.6 (d, 1), 4.9 (s, 2), 4.7 (m, 2), 4.4 (m, 1), 3.4-3.6 (m, 3), 3.0 (m, 1) 2.8 (m,1), 2.6 (d, 1), 2.2 (m, 1), 2.0 (m, 1), 1.2-1.4 (m, 3) ppm.
Example 7
Preparation of 1 -(2-{2-[(2/?)-4-(4-Fluorobenzyl)-2-methylpiperazin-1 -yl]-2-oxoethoxy}-5- iodo-123 phenyl)urea
A. To a solution of the compound of formula (n) (1 mg), as prepared above, and 10 μg copper-(ll)-sulfate in 300 μl DMF was added 1 mCi sodium iodine[123l] solution. The resulting reaction mixture was heated over night to 100°C. After adding of 1 mL half-
saturated aqueous NaHC03 solution the product was extracted with 2 mL CH2CI2. The organic layer was evaporated to dryness in a nitrogen gas stream. The desired product, 1-(2- {2-[(2f?)-4-(4-fluorobenzyl)-2-methylpiperazin-1-yl]-2-oxoethoxy}-5-iodo-123/-phenyl)urea, was purified using a RP-cartridge [eluant: EtOH/water (2:1)]. B. In a similar manner as described above, other compounds of formula (I) are prepared.
Example 8 Λ '-(2-Mercaptoeth-1-yl)-/V-(5-mercapto-3-aza-2-oxopent-1-yl)-Λf-{5-chloro-2-[2-[4-(4- f luorobenzyl)-2-(2f?)-methylpiperazin-1 -yl]-2-oxoethoxy]phen-1 -yl}glycinamide,
Technetium-99m-complex
A. To a stirred solution of 156J mg (0.4 mmol) 5-chIoro-2-[2-[4-(4-fluorobenzyl)-2- (2R)-methylpiperazin-1-yl]-2-oxoethoxy]aniline (compound of formula (i)) (291.4 mg, 0.4 mmol), /V-(S-trityl-2-mercaptoeth-1 -yl)-Λ/-(S-trityl-5-mercapto-3-aza-2-oxopent-1 -yl)glycine (synthesized according to A. Mahmood etal., A N2S2-Tetradentate Chelate for Solid-Phase Synthesis: Technetium, Rhenium in Chemistry and Nuclear Medicine (1999), Vol. 5, p. 71) and Λ/-hydroxysuccinimide (45.5 mg, 0.4 mmol) in 5 mL dichloromethane was added dropwise a solution of dicyclohexylcarbodiimide (81.4 mg, 0.4 mmol) in 3 mL dichloromethane. The resulting suspension was stirred over night at ambient temperature. After filtration, the resulting solution was evaporated under reduced pressure. The desired product, Λ/'-(S-trityl-2-mercaptoeth-1-yl)-Λ/'-(S-trityl-5-mercapto-3-aza-2-oxopent-1-yl)-Λ/-{5- chloro-2-[2-[4-(4-fluorobenzyl)-2-(2R)-methylpiperazin-1 -yl]-2-oxoethoxy]phen-1- yl}glycinamide (352 mg, 79.2%), was isolated after silica gel chromatography (eluent: dichloromethane/methanol, 98:2) as a white powder. Elemental Analysis:
Calc: C 71.36 H 5.90 N 6.30 O 5.76 S 5J7
Found: C 71.08 H 6.13 N 6.05 O S 5.52
B. Λ/'-(S-trityl-2-mercaptoeth-1 -yl)-Λ/'-(S-trityl-5-mercapto-3-aza-2-oxopent-1 -yl)-Λ/- {5-chloro-2-[2-[4-(4-fluorobenzyl)-2-(2f?)-methylpiperazin-1-yl]-2-oxoethoxy]phen-1- yl}glycinamide (111.1 mg, 0.1 mmol) was dissolved in 5 mL trifluoroacetic acid. After addition
of 48 μl (0.3 mmol) triethyl silane the resulting suspension was stirred for 15 min at ambient temperature. The titrate was evaporated under reduced pressure and the residue was triturated with 7 mL diethyl ether. The precipitate was stirred for 1 hour at ambient temperature and filtered off, yielding the desired product, A/'-(2-mercaptoeth-1-yl)-/V-(5- mercapto-3-aza-2-oxopent-1-yl)-Λ/-{5-chloro-2-[2-[4-(4-fluorobenzyl)-2-(2R)-methylpiperazin- 1 -yl]-2-oxoethoxy]phen-1 -yl}glycinamide, bis-trifluoracetic acid salt (75 mg, 87.8%) as a white solid.
Elemental Analysis:
Calc: C 44.99 H 4.60 N 8.20 O 14.98 S 7.51 Found: C 44.71 H 4.89 N 8.03 O S 7.22
C. Disodium tartrate (1 mg) disodium tartrate and /V-(2-mercaptoeth-1 -yl)-/V-(5- mercapto-3-aza-2-oxopent-1-yl)-Λ/-{5-chloro-2-[2-[4-(4-fluorobenzyl)-2-(2/:?)-methylpiperazin- 1-yl]-2-oxoethoxy]phen-1 -yl}glycinamide, bis-trifluoracetic acid salt (100 μg) were dissolved in 500 μl sodium phosphate buffer (0.1 M, pH=8.5). After addition of 37.5MBq 99mTc-generator eluate, 5 μl tin-(ll) chloride solution was added and the mixture was heated for 10 minutes to 100°C. HPLC-analysis showed a major peak indicating that the desired product, Λ/'-(2- mercaptoeth-1-yl)-Λ/'-(5-mercapto-3-aza-2-oxopent-1-yl)-/V-{5-chloro-2-[2-[4-(4-fluorobenzyl)- 2-(2f?)-methylpiperazin-1 -yl]-2-oxoethoxy]phen-1 -yljglycinamide, technetium-99m-complex was synthesized with a RCP > 91%.
Example 9 Λ/,-(2-Mercaptoeth-1-yl)- /'-(5-mercapto-3-azapent-1-yl)-Λ/-{5-chloro-2-[2-[4-(4- fluorobenzyl)-2-(2fl)-methylpiperazin-1-yl]-2-oxoethoxy]phen-1-yl}glycinamide,
Technetium-99m-complex A. To a stirred solution of 5-chloro-2-[2-[4-(4-fluorobenzyl)-2-(2f?)-methylpiperazin-
1 -yl]-2-oxoethoxy]aniline (156.7 mg, 0.4 mmol) and triethylamine (40.5 mg, 0.4 mmol) in 5 mL dichloromethane was added dropwise a solution of -bromoacetyl chloride (63 mg, 0.4 mmol) in 3 mL dichloromethane. The resulting solution was stirred over night at ambient temperature. The solvent was evaporated under reduced pressure. The desired product, N-{5-chloro-2-[2-[4-(4-fluorobenzyl)-2-(2 :?)-methylpiperazin-1-yl]-2-oxoethoxy]phen-1-yl}-2-
bromoacetamide (175 mg, 85.3 %), was isolated after silica gel chromatography (eluent: dichloromethane/methanol, 99:1 ) as a white powder.
Elemental Analysis:
Calc: C 51.53 H 4.72 N 8.19 O 5.76 Found: C 51.28 H 4.99 N 7.92 O
B. A stirred solution of Λ/-{5-chloro-2-[2-[4-(4-fluorobenzyl)-2-(2/:?)-methylpiperazin- 1-yl]-2-oxoethoxy]phen-1-yl}-2-bromoacetamide (165 mg, 0.42 mmol) and N,N-b\s-(S-(4- methoxybenzyl)-2-mercaptoeth-1-yl)ethylenediamine (841.3 mg, 2 mmol) (synthesized according to Z.P. Zhuang et al., Bioconjugate Chem. (1999), Vol. 10, p. 159) in 1 ,4-dioxane (5 mL) was heated under reflux for 24 hours. The resulting reaction mixture was evaporated under reduced pressure. The residue was dissolved in 15 mL dichloromethane and washed with saturated aqueous sodium carbonate solution. After drying over MgS0 the solvent was evaporated under reduced pressure. The desired product, V-(S-(4-methoxybenzyl)-2- mercaptoeth-1-yl)-/V-(S-(4'-methoxybenzyl)-5-mercapto-3-azapent-1-yl)-Λ/-{5-chloro-2-[2-[4- (4-fluorobenzyl)-2-(2 :?)-methylpiperazin-1 -yl]-2-oxoethoxy]phen-1 -yl}glycinamide (154 mg, 43%), was isolated after silica gel chromatography (eluent: dichloromethane/methanol, 9:1) as a white powder.
Elemental Analysis:
Calc: C 61.99 H 6.50 N 8.22 O 9.38 S 7.52 Found: C 61.71 H 6.58 N 8.03 O S 7.28
C. /V-(S-(4-methoxybenzyl)-2-mercaptoeth-1-yl)-Λ/'-(S-(4'-methoxybenzyl)-5- mercapto-3-azapent-1 -yl)-Λ/-{5-chloro-2-[2-[4-(4-fluorobenzyl)-2-(2R)-methylpiperazin-1-yl]-2- oxoethoxy]phen-1-yl}glycinamide (140 mg, 0.164 mmol) was dissolved at 0°C in 5 mL trifluoroacetic acid. After addition of Hg(OAc)2 (104.5 mg, 0.328 mmol) the resulting mixture was stirred for 30 minutes at 0°C and saturated for 15 min with H2S. After filtration the solvent was evaporated under reduced pressure. The resulting yellow oil was triturated with 3 mL diethyl ether. The desired product, Λ/'-(2-mercaptoeth-1-yl)-Λ/'-(5-mercapto-3-azapent- 1 -yl)-/V-{5-chloro-2-[2-[4-(4-fluorobenzyl)-2-(2f?)-methylpiperazin-1 -yl]-2-oxoethoxy]phen-1 - yl}glycinamide, tris-trifluoracetic acid salt (126 mg (80.5%), was isolated after filtration as a white powder.
Elemental Analysis:
Calc: C 42.79 H 4.44 N 7.34 O 15.09 S 6.72
Found: C 42.48 H 473 N 7.02 O S 6.76
D. Disodium tartrate (1 mg) and Λ/'-(2-mercaptoeth-1-yl)-Λ/'-(5-mercapto-3- azapent-1 -yl)-/V-{5-chloro-2-[2-[4-(4-fluorobenzyl)-2-(2R)-methylpiperazin-1 -yl]-2- oxoethoxy]phen-1-yl}glycinamide, tris-trifluoracetic acid salt (100 μg) were dissolved in 500 μl sodium phosphate buffer (0.1 M, pH=8.5). After addition of 37.5MBq 99mTc-generator eluate, 5 μl tin-(ll) chloride solution was added and the mixture was heated for 10 minutes to 100°C. HPLC-analysis showed a major peak indicating that the desired product, -(2-mercaptoeth- 1 -yl)-/V-(5-mercapto-3-azapent-1 -yl)-Λ/-{5-chloro-2-[2-[4-(4-fluorobenzyl)-2-(2ft)- methylpiperazin-1 -yl]-2-oxoethoxy]phen-1 -yljglycinamide, Technetium-99m-complex, was synthesized with a RCP > 95%.
Example 10 Immunohistochemical Localization of CCR1 in Human Brains
Materials and Methods
A first group of tissue samples from brains that had been obtained at autopsy within
12 hours of death was used for immunohistochemical staining of the chemokine receptor
CCR1 in Alzheimer's disease and control brains. Paraffin-embedded, 5-μm-thick, unstained sections from frontal cortex and hippocampus were used for all immunohistochemical and histochemical stains.
Slides were de-paraffinized in xylene and hydrated to phosphate-buffered saline containing 0.005% Triton X100 (PBS-T). For light microscopy (using DAB as chromogen) endogenous peroxidase activity was blocked by incubating the slides with 0.01% H202 in methanol for 30 minutes. Non-specific binding was reduced by blocking in 10% normal goat serum (NGS) in PBS for 30 minutes. The primary antibodies [Rabbit anti-CCR1 , (N- terminal peptide); Mouse anti-Neurofilament; mouse anti-GFAP; mouse anti-Tau (AT8); mouse anti-CD68 (clone KP1); mouse anti-β-amyloid (Boehringer Mannheim, #1 381 431);
Rabbit anti-CCR8, (N-terminal peptide)] were diluted in PBS-T and slides were incubated overnight at room temperature. Staining was completed using a Biogenex ABC™ kit. All
washes used PBS-T. After the DAB reaction was completed, slides were lightly counterstained with Gill's Hematoxylin, dehydrated and coverslipped with Permount. Before coverslipping, some slides were re-stained with antibodies against Aβ peptide using identical methods except that the chromogen was True Blue™. For immunofluorescent double-labeling studies the slides were de-paraffinized, blocked with 10% NGS, and incubated with a cocktail of both primary antibodies overnight. The slides were washed with PBS-T and then incubated with a cocktail of goat secondary antibodies, each at 1/50 dilution. To avoid confusion from endogenous (yellow-green) tissue fluorescence, the secondary antibodies were conjugated to either Cy3 (εmax = 565 nm; goat-anti-mouse, Amersham) or Cy5 (εmaχ=700 nm; goat-anti-rabbit, Amersham). Slides were viewed on a confocal microscope with a krypton-argon laser (model 2010, Molecular Dynamics, Sunnyvale, CA).
Subsequently, a second group of brain tissues composed of 10 cases from cognitively normal elderly and 40 cases from Alzheimer's disease patients who had been assessed for clinical dementia rating (CDR) were obtained and evaluated for immunohistochemical expression of CCR1. The samples were stained for CCR1 and other markers as described above except that monoclonal antibodies (clone #6D5) specific for Aβ1"42 (a marker for diffuse, early amyloid deposits as well as for more mature neuritic plaques) were obtained from Dr. Ursula Moenning. These antibodies were visualized with Vector Red™ (Vector Labs). Dr Moenning also provided monoclonal antibodies specific for Aβ1"40 (clone #13E9), a marker for plaques found in late-stage disease, that was visualized with True Blue™.
Results In both sets of brains, areas with Alzheimer's disease pathology showed a characteristic staining pattern. CCR1 immunoreactivity was found in association with neuritic (i.e., senile) plaques in both the hippocampal formation and the cerebral cortex. The immunostained structures were round to ovoid and were not usually associated with cell bodies. They varied in size and appeared to be filled with a punctate granular material. These structures were found to form "coronas" around the amyloid deposits in
senile plaques, but were distinct from the Aβ itself (Figures 1-4). The top panel in Figure 1 shows a neuritic plaque with a corona of CCR1 -positive processes. Neuronal cell bodies of some CA1 and CA3 neurons in Alzheimer's disease cases were sometimes stained by CCR1 antibodies. The bottom panel in Figure 1 illustrates this finding. This staining was distinct from neurofibrillary tangles (NFT) or granulovacuolar bodies, although it was commonly present in the somata of neurons with these degenerative changes.
Pre-incubation of antibodies with a 16-mer polypeptide from the extracellular (Λ/-terminus) region of the CCR1 receptor protein completely blocked all tissue staining, as illustrated in Figure 2. In particular, the top image in Figure 2 shows a lack of staining in Alzheimer's disease brain with CCR1 antibodies that were pre-incubated with the polypeptide while the bottom image in Figure 2 shows many CCR1 -positive structures in a sister section stained with un-incubated antibodies.
Double-labeling studies showed that nearly all CCR1 -positive structures were associated with neuritic plaques containing Aβ1"42 as shown in Figure 4. Aβ1"42 in diffuse plaques (Figure 5) was not typically associated with CCR1 nor with any significant cellular responses. In more advanced cases of Alzheimer's disease, many more Aβ1"40-positive plaques were seen. Some, but not all of these were associated with CCR1 staining as shown in Figure 3. In some cases CCR1 -positive plaques were completely free of Aβ1"40 staining. In cases of severe Alzheimer's disease where significant neuronal loss and gliosis were seen, reactive astrocytes in the subiculum and entorhinal cortex were also CCR1 positive. In less severe cases, CCR1 -positive reactive astrocytes were uncommon.
Confocal microscopy of double-labeled sections showed that CCR1 immunoreactivity co-localized with neurofi lament-positive processes. The macrophage/microglial marker, CD68, was not associated with CCR1 staining, nor was the AT8 antibody against abnormally phosphorylated tau protein. As expected from light microscopic studies, CCR1 immunoreactivity did co-localize with GFAP in areas of astrogliosis.
Leukocytes present within cerebral vessels were strongly CCR1 positive in both Alzheimer's disease and control brain tissues, serving as positive internal controls for staining methods. In Figure 5 note the CCR1 -positive staining of two intravascular cells
(arrows). Some CCR1 -positive material is also seen at asterisk, but in general, diffuse plaques are not associated with CCR1.
Using hippocampal tissue from the second study (where patients were grouped into known clinical categories by CDR score), a quantitative evaluation of the number of CCR1- positive plaque-like structures in the hippocampus was undertaken. Histologic evaluations of individual sections were performed under blinded conditions with respect to clinical (CDR) status. The volume analyses were conducted using unbiased computerized methods.
Figure 3 demonstrates the histologic relationship between CCR1 -positive dystrophic neurites (brown stain) and a neuritic plaque containing Aβ1"40 (blue stain). Note in that in Figure 3 the CCR1 -positive processes are distinct from the amyloid. Plaques containing Aβ1"40 were discrete and easily counted, as were the clusters of CCR1 -positive neurites. Slides of hippocampus were evaluated for the number of CCR1 -positive coronas, the number of Aβ1"40 positive plaques, and the number of plaques containing both markers. The structures were counted by region (e.g., CA3, CA1 , and subiculum) within the entire hippocampal formation, including entorhinal cortex and then totaled. The values are relative estimates of the number of structures in the hippocampus as represented by 5-μm thick cross-sections of the hippocampal formation. Figure 6 shows the relationship between CCR1 and Aβ1"40 by CDR score. Quantification of the amount of Aβ1"42 required a different technique because Aβ1"42 was more abundant and formed "diffuse" plaques that could not be easily enumerated (see Figure 5). For these slides a computer-assisted method (C.A.S.T. stereology system) was used to estimate the area of entorhinal cortex occupied by Aβ1"42. This area was expressed as a percent of the total area of cortex on the slide. The areas occupied by neuritic and diffuse plaques were counted separately. The computer-driven microscope stage assured random (unbiased) evaluation of the tissue sections. The volume % of entorhinal cortex occupied by Aβ1"42 (both diffuse and neuritic) is compared to the number of CCR1 -positive plaques in a sister section of entorhinal cortex in Figure 7.
Figure 6 shows that the average number of CCR1 -positive dystrophic neurites in the hippocampus increases as a function of CDR score in Alzheimer's disease. The number
of positive structures in early Alzheimer's disease (CDR 0.5) is increased above control (CDR 0) levels. Although the differences between control and Alzheimer's disease groups did not become statistically significant until group CDR 2, these expression patterns support the conclusion that CCR1 is upregulated in dystrophic neuronal processes even at very early stages of Alzheimer's disease. Note that the number of Aβ1"40 plaques do not rise until late in the disease. CCR1 expression in brain tissue may thus be considered a relatively early indicator of Alzheimer's disease.
The correlation between number of CCR1 -positive plaques in entorhinal cortex and the amount of Aβ1"42 is shown in Figure 7. In general, CCR1 levels in entorhinal cortex rise as the disease state increases; however, the area sampled is much smaller than the area sampled in Figure 6. Note, however, that Aβ1"42 levels rise early in the disease.
Example 11 Assessment of brain availability, using a 14C-labeled tracer A C analogue of 1-(5-chloro-2-{2-[(2/:?)-4-(4-fluorobenzyl)-2-methylpiperazin-1-yl]-
2-oxoethoxy}phenyl)urea was prepared and used for pharmacokinetic studies of brain availability. Mice were injected i.v. through cannulated jugular veins with the analogue at 36 mg/kg containing 334,000 dpm per dose. Mice (in groups of four) were sacrificed at 1 , 15, 30, 120, and 1440 minutes after injection by C02 inhalation followed by intra-cardiac puncture for removal of whole blood. The chest was then opened and mice were perfused through the heart with phosphate buffered saline for five minutes to remove residual radioactive drug from the blood compartment. The brains were then removed, weighed, and sampled for amount of radioactivity in two separate pieces of cerebral cortex. The radioactivity levels per mg of tissue in the two samples were averaged and the data were normalized to total brain weight, as illustrated in Figure 8. The bars represent the standard error (n=4 mice per time point). In particular, the graph in Figure 8 shows that the total number of disintegrations per minute (DPM) for 14C analogue in whole mouse brain decreases to negligible levels by two hours after injection. At the 1 -minute time point, calculations show that, on average, about 3% of the injected dose is found in whole mouse brain (average weight of 450 g).
Plasma samples prepared from the whole blood removed from the mice were also analyzed for radioactive content. The amount of radioactivity in equal volumes of brain and plasma was compared over time as a percent of injected dose, as illustrated in Figure 9. The % of injected dose (i.d.) found per mL of plasma also declines over time, reaching negligible levels after two hours. For comparison to brain levels, the total number of DPM per brain were normalized to a gram of brain weight and expressed as a percentage of the i.d. per gram of brain tissue. Note that mouse brains weigh on average about 450 mg so that the % of i.d. in 1 g of mouse brain shown in the graph overestimates the real value by about twofold. It is clear that the levels of the analogue in the brain fall in concert with plasma levels. Although the analogue is lipophilic, normal mouse brain does not appear to be a depot site for the CCR1 antagonist.
Example 12 CCR1 Expression in Other Neurodegenerative Diseases Materials and Methods
Histologic samples of autopsy brain tissue from a total of 29 cases from seven different neurodegenerative diseases (other than pure Alzheimer's disease) were obtained and studied for CCR1 content. Slides were immunostained with antibodies against CCR1 as described in Example 10 above and reviewed under blinded conditions with respect to the specific neurodegenerative disease. Subsequently, sister sections were double-labeled with antibodies against CCR1 (DAB as chromogen) and Aβ1"42 (Vector Red™ as chromogen). The diseases examined are listed below:
Parkinson's disease (PD) 6 cases
Parkinsonian dementia of Guam 3 cases Congophilic angiopathy 4 cases
Multi-infarct dementia (MID) 4 cases
Diffuse Lewy body dementia (DLBD) 4 cases Pick's disease 4 cases
Progressive supranuclear palsy (PSP) 4 cases The stained slides were graded for CCR1 and Aβ1"42 content using a histologic scale
of 0 to 4, with 0 being absence of staining, 0.5 indicating rare expression, and grades 1 through 4 indicating increasing levels of expression with 4 being highly abundant.
Results All six cases of Parkinson's disease and all three cases of Parkinsonian dementia of
Guam were negative for CCR1. CCR1 -positive plaque-like structures, similar to those found in Alzheimer's disease, were observed in all 4 cases of congophilic angiopathy, in 3 of the 4 cases of DLBD, in 2 out of the 4 cases of PSP, and in 1 out of the 4 cases of both MID and Pick's disease. Double-labeling studies confirmed the assumption that these CCR1 -positive plaquelike structures were associated with Aβ1"42, as was found in pure cases of Alzheimer's disease (Example 10). Figure 10 shows the results of the pathological evaluations in graphic form for all the diseases except for Parkinson's (which was negative for CCR1 in brain). Basically, CCR1 expression was never found in brain tissue samples unless Aβ1'42-positive neuritic plaques were also present.
After the code was broken, it was found that the one case of Pick's disease showing CCR1 expression also carried the diagnosis of Alzheimer's disease. The two PSP cases with CCR1 were also diagnosed with concurrent Alzheimer's disease. Congophilic angiopathy and DLBD are diseases that are closely associated with Alzheimer's disease pathology. Therefore, it is not surprising that they would also have high levels of CCR1 expression in association with Aβ1"42. In elderly populations it is often the case that Alzheimer's disease pathology will overlay other disease processes. This was found in one of the four MID cases. These results suggests that CCR1 is a marker that is closely associated with Alzheimer's disease pathology (specifically, Aβ1 42-positive neuritic plaques) regardless of other concurrent pathological processes that may be present in brain. As such, it is likely to be highly specific for Alzheimer's disease pathology and therefore may be useful as a diagnostic surrogate marker of disease progression.
* * * * * While the present invention has been described with reference to the specific
embodiments thereof, it should be understood by those skilled in the art that various changes may be made and equivalents may be substituted without departing from the true spirit and scope of the invention. In addition, many modifications may be made to adapt a particular situation, material, composition of matter, process, process step or steps, to the objective, spirit and scope of the present invention. All such modifications are intended to be within the scope of the claims appended hereto.
Claims (1)
- What is claimed is:A compound of formula (I):wherein:X1 and X2 are each independently halo;R1 and R2 are each independently hydrogen or alkyl; andR3 is hydrogen, amino, monoalkylamino, dialkylamino, monoaralkylamino, alkylcarbonylamino, alkenylcarbonylamino, haloalkylcarbonylamino, arylcarbonylamino, alkoxyalkylcarbonylamino, alkoxycarbonylalkylcarbonylamino, glycinamido, monoalkylglycinamido, arylcarbonylglycinamido, aminocarbonylglycinamido, (aminocarbonyl)(alkyl)glycinamido, (alkoxyalkylcarbonyl)glycinamido, ureido, monoalkylureido, monoarylureido, monoaralkylureido, or alaninamido; and wherein either one of X1 or X2 is selected from the group of 123l, 125l, 128l, 131l, 75Br, 76Br, 80Br and 18F; or wherein one of the carbon atoms in the compound is 11C; or a pharmaceutically acceptable salt thereof.A compound of formula (II):whereinX1 and X2 are each independently halo;R1 and R2 are each independently hydrogen or alkyl; andR4 is hydrogen; andR5 comprises a chelator capable of binding a radioactive metal atom chosen from the group of 99mTc, 186Re and 188Re; or as a complex with 99mTc, 186Re and 188Re; or a pharmaceutically acceptable salt thereof.3. The compound of Claim 1 or Claim 2 wherein said compound binds to chemokine receptor CCR1 and passes the blood-brain barrier.4. The compound of Claim 1 or Claim 2 wherein R1 is methyl at the 2-position of the piperazinyl radical and R2 is methyl at the 5-position of the piperazinyl radical.5. The compound of Claim 1 or Claim 2 wherein R1 is methyl at the 2-position of the piperazinyl radical and R2 is hydrogen.6. The compound of Claim 1 wherein X1 is chloro at the 4-position of the phenyl radical and X2 is a 18F atom at the 4-position of the phenyl radical.7. The compound of Claim 2 wherein R5 is a chelator of formula (III):8. The compound of Claim 2 wherein R5 is a chelator of formula (IV)9. The compound of Claim 7 or Claim 8 wherein R5 further comprises a linker moiety comprising an alkyl radical having one to ten carbon atoms, wherein the alkyl radical optionally contains one to ten -C(0)-groups, one to ten -C(0)N(R)- groups, one to ten -N(R)C(0)- groups, one to ten -N(R)- groups, one to ten -N(R)2 groups, one to ten hydroxy groups, one to ten -C(0)OR- groups, one to ten oxygen atoms, one to ten sulfur atoms, one to ten nitrogen atoms, one to ten halogen atoms, one to ten aryl groups, and one to ten saturated or unsaturated heterocyclic rings wherein R is hydrogen or alkyl.0. The compound of Claim 9 wherein the linker moiety is -C(0)-CH2-N(H).11. The monochloride salt of a compound of Claim 1 to Claim 10.12. The dichloride salt of a compound of Claim 1 to Claim 10.13. A method of diagnosing Alzheimer's disease in a human which comprises administering to a human in need of such diagnosis a compound according to Claim 1 to 12 and measuring the radioactivity arising from the administration of the compound to the human either by using a gamma camera or by positron emission tomography (PET).14. A method of using a compound according to Claim 1 to 12 for the manufacture of a radiopharmaceutical for the diagnosis of Alzheimer's disease in a human.15. A process for the production of a compound of formula (I) according to Claim 1 comprising the reaction of a compound of formula (f):(f) wherein R1, R2, R3 and X1 are as defined in Claim 1, with a compound of formula (b):(b) in the presence of a reducing agent.
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US24629900P | 2000-11-06 | 2000-11-06 | |
| US60/246,299 | 2000-11-06 | ||
| PCT/EP2001/012607 WO2002036581A1 (en) | 2000-11-06 | 2001-11-01 | Radiopharmaceuticals for diagnosing alzheimer's disease |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| AU2002214034A1 true AU2002214034A1 (en) | 2002-07-18 |
| AU2002214034B2 AU2002214034B2 (en) | 2006-01-05 |
Family
ID=22930075
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AU2002214034A Ceased AU2002214034B2 (en) | 2000-11-06 | 2001-11-01 | Radiopharmaceuticals for diagnosing alzheimer's disease |
| AU1403402A Pending AU1403402A (en) | 2000-11-06 | 2001-11-01 | Radiopharmaceuticals for diagnosing alzheimer's disease |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AU1403402A Pending AU1403402A (en) | 2000-11-06 | 2001-11-01 | Radiopharmaceuticals for diagnosing alzheimer's disease |
Country Status (29)
| Country | Link |
|---|---|
| US (2) | US6676926B2 (en) |
| EP (1) | EP1332138B1 (en) |
| JP (1) | JP4234425B2 (en) |
| KR (1) | KR20030045167A (en) |
| CN (1) | CN1473158A (en) |
| AR (1) | AR035366A1 (en) |
| AT (1) | ATE314354T1 (en) |
| AU (2) | AU2002214034B2 (en) |
| BG (1) | BG107762A (en) |
| BR (1) | BR0115150A (en) |
| CA (1) | CA2424598A1 (en) |
| DE (1) | DE60116365T2 (en) |
| EA (1) | EA006199B1 (en) |
| EE (1) | EE200300216A (en) |
| HR (1) | HRP20030459A2 (en) |
| HU (1) | HUP0301710A3 (en) |
| IL (1) | IL155191A0 (en) |
| JO (1) | JO2207B1 (en) |
| MX (1) | MXPA03003759A (en) |
| NO (1) | NO20032007L (en) |
| NZ (1) | NZ525303A (en) |
| PE (1) | PE20020531A1 (en) |
| PL (1) | PL361631A1 (en) |
| SK (1) | SK287495B6 (en) |
| TW (1) | TWI238820B (en) |
| UY (1) | UY27003A1 (en) |
| WO (1) | WO2002036581A1 (en) |
| YU (1) | YU33203A (en) |
| ZA (1) | ZA200304409B (en) |
Families Citing this family (25)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| UY27003A1 (en) * | 2000-11-06 | 2002-07-31 | Schering Ag | RADIOPHARMACEUTICAL PRODUCTS FOR THE DIAGNOSIS OF ALZHEIMER'S DISEASE |
| PL370548A1 (en) | 2001-10-22 | 2005-05-30 | Pfizer Products Inc. | Piperazine derivatives with ccr1 receptor antagonist activity |
| WO2003059884A1 (en) | 2001-12-21 | 2003-07-24 | X-Ceptor Therapeutics, Inc. | Modulators of lxr |
| US7482366B2 (en) | 2001-12-21 | 2009-01-27 | X-Ceptor Therapeutics, Inc. | Modulators of LXR |
| JP2006525279A (en) * | 2003-05-07 | 2006-11-09 | シエーリング アクチエンゲゼルシャフト | Nucleophilic fluorination apparatus and method |
| US9017724B2 (en) | 2004-02-24 | 2015-04-28 | The General Hospital Corporation | Catalytic radiofluorination |
| CA2825161C (en) * | 2004-02-24 | 2016-10-04 | The General Hospital Corporation | Catalytic radiofluorination |
| US8257680B1 (en) | 2004-02-24 | 2012-09-04 | The General Hospital Corporation | Catalytic radiofluorination |
| GB0409236D0 (en) * | 2004-04-26 | 2004-05-26 | Novartis Ag | Organic compounds |
| US7833513B2 (en) | 2004-12-03 | 2010-11-16 | Rhode Island Hospital | Treatment of Alzheimer's Disease |
| KR100778888B1 (en) * | 2005-11-29 | 2007-11-28 | 재단법인서울대학교산학협력재단 | Benzylidene aniline derivatives and their radioisotope compounds for imaging of beta amyloid peptide plaques |
| WO2008030604A2 (en) | 2006-09-08 | 2008-03-13 | Rhode Island Hospital | Treatment, prevention, and reversal of alcohol-induced brain disease |
| EP2061484B1 (en) | 2006-09-08 | 2012-11-07 | Rhode Island Hospital | Treatment, prevention, and reversal of alcohol-induced liver disease |
| GB0625523D0 (en) | 2006-12-21 | 2007-01-31 | Ge Healthcare Ltd | In vivo imaging agents |
| WO2008075043A1 (en) * | 2006-12-21 | 2008-06-26 | Hammersmith Imanet Limited | Radiolabelling methods |
| CA2703563A1 (en) * | 2007-10-31 | 2009-05-07 | Alseres Pharmaceuticals, Inc. | Methods for diagnosing and monitoring treatment of lewy body dementia by assessing dopamine transporter level |
| JP5501339B2 (en) | 2008-03-21 | 2014-05-21 | ザ ジェネラル ホスピタル コーポレイション | Compounds and compositions for detection and treatment of Alzheimer's disease and related diseases |
| EP2161256A1 (en) * | 2008-09-08 | 2010-03-10 | Atomic Energy Council - Institute of Nuclear Energy Research | Compound containing carboxylate ester and N2S2 ligand bi-functional groups and manufacturing method thereof |
| EP2163541A1 (en) * | 2008-09-12 | 2010-03-17 | Bayer Schering Pharma Aktiengesellschaft | Piperazine derivatives for binding and imaging amyloid plaques and their use |
| WO2011041470A2 (en) * | 2009-09-30 | 2011-04-07 | Mallinckrodt Inc. | Sustained-release opiate and opiate derivative compositions |
| TW201201846A (en) * | 2010-02-08 | 2012-01-16 | Bayer Schering Pharma Ag | Iodo precursor for a PET imaging agent of amyloid plaques |
| WO2011110511A1 (en) * | 2010-03-11 | 2011-09-15 | Bayer Pharma Aktiengesellschaft | Spect imaging agents of amyloid plaques |
| US9572787B2 (en) | 2011-05-19 | 2017-02-21 | Rhode Island Hospital | Inhibition of renal fibrosis |
| EP4321165A3 (en) | 2013-12-27 | 2024-08-21 | National University Corporation Tokyo Medical and Dental University | Method for diagnosis of alzheimer's disease and frontotemporal lobar degeneration, diagnostic agent, therapeutic agent, and screening method for said agents |
| HRP20211156T1 (en) | 2015-08-28 | 2021-12-24 | Chdi Foundation, Inc. | Probes for imaging huntingtin protein |
Family Cites Families (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPH06510021A (en) | 1991-03-13 | 1994-11-10 | ザ リージェンツ オブ ザ ユニバーシティ オブ ミネソタ | Radioactive drug for Alzheimer's disease detection |
| EP0524146A1 (en) | 1991-07-19 | 1993-01-20 | Ciba-Geigy Ag | Aminosubstituted Piperazinederivatives |
| GB9413772D0 (en) | 1994-07-08 | 1994-08-24 | Wyeth John & Brother Ltd | 5-HT1A ligands |
| AU2680797A (en) * | 1996-04-24 | 1997-11-12 | Emory University | Halogenated naphthyl methoxy piperidines for mapping serotonin transporter sites |
| JP2000516210A (en) | 1996-07-12 | 2000-12-05 | ロイコサイト，インコーポレーテッド | Chemokine receptor antagonists and methods of use |
| FR2758328B1 (en) | 1997-01-15 | 1999-04-02 | Pf Medicament | NEW AROMATIC AMINES DERIVED FROM CYCLIC AMINES USEFUL AS MEDICAMENTS |
| US6207665B1 (en) * | 1997-06-12 | 2001-03-27 | Schering Aktiengesellschaft | Piperazine derivatives and their use as anti-inflammatory agents |
| AUPP278498A0 (en) * | 1998-04-03 | 1998-04-30 | Australian Nuclear Science & Technology Organisation | Peripheral benzodiazepine receptor binding agents |
| US6288083B1 (en) | 1998-09-04 | 2001-09-11 | Millennium Pharmaceuticals, Inc. | Chemokine receptor antagonists and methods of use therefor |
| AUPP818099A0 (en) | 1999-01-14 | 1999-02-11 | Fujisawa Pharmaceutical Co., Ltd. | New n-containing heterocyclic compounds |
| PL350904A1 (en) | 1999-03-26 | 2003-02-10 | Astrazeneca Ab | Novel compounds |
| UY27003A1 (en) * | 2000-11-06 | 2002-07-31 | Schering Ag | RADIOPHARMACEUTICAL PRODUCTS FOR THE DIAGNOSIS OF ALZHEIMER'S DISEASE |
-
2001
- 2001-10-31 UY UY27003A patent/UY27003A1/en not_active Application Discontinuation
- 2001-11-01 EA EA200300507A patent/EA006199B1/en not_active IP Right Cessation
- 2001-11-01 HU HU0301710A patent/HUP0301710A3/en unknown
- 2001-11-01 WO PCT/EP2001/012607 patent/WO2002036581A1/en not_active Ceased
- 2001-11-01 EE EEP200300216A patent/EE200300216A/en unknown
- 2001-11-01 HR HR20030459A patent/HRP20030459A2/en not_active Application Discontinuation
- 2001-11-01 CA CA002424598A patent/CA2424598A1/en not_active Abandoned
- 2001-11-01 KR KR10-2003-7006187A patent/KR20030045167A/en not_active Withdrawn
- 2001-11-01 NZ NZ525303A patent/NZ525303A/en unknown
- 2001-11-01 JP JP2002539340A patent/JP4234425B2/en not_active Expired - Fee Related
- 2001-11-01 DE DE60116365T patent/DE60116365T2/en not_active Expired - Lifetime
- 2001-11-01 EP EP01982450A patent/EP1332138B1/en not_active Expired - Lifetime
- 2001-11-01 IL IL15519101A patent/IL155191A0/en unknown
- 2001-11-01 CN CNA01818409XA patent/CN1473158A/en active Pending
- 2001-11-01 AT AT01982450T patent/ATE314354T1/en not_active IP Right Cessation
- 2001-11-01 YU YU33203A patent/YU33203A/en unknown
- 2001-11-01 AU AU2002214034A patent/AU2002214034B2/en not_active Ceased
- 2001-11-01 PL PL01361631A patent/PL361631A1/en not_active Application Discontinuation
- 2001-11-01 MX MXPA03003759A patent/MXPA03003759A/en unknown
- 2001-11-01 SK SK547-2003A patent/SK287495B6/en not_active IP Right Cessation
- 2001-11-01 AU AU1403402A patent/AU1403402A/en active Pending
- 2001-11-01 BR BR0115150-9A patent/BR0115150A/en not_active IP Right Cessation
- 2001-11-02 AR ARP010105127A patent/AR035366A1/en unknown
- 2001-11-05 JO JO2001178A patent/JO2207B1/en active
- 2001-11-05 PE PE2001001092A patent/PE20020531A1/en not_active Application Discontinuation
- 2001-11-06 TW TW090127552A patent/TWI238820B/en not_active IP Right Cessation
- 2001-11-06 US US09/985,938 patent/US6676926B2/en not_active Expired - Fee Related
-
2003
- 2003-04-25 BG BG107762A patent/BG107762A/en unknown
- 2003-05-05 NO NO20032007A patent/NO20032007L/en unknown
- 2003-06-05 ZA ZA200304409A patent/ZA200304409B/en unknown
- 2003-07-25 US US10/626,725 patent/US6872381B1/en not_active Expired - Fee Related
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EP1332138B1 (en) | Radiopharmaceuticals for diagnosing alzheimer's disease | |
| AU2002214034A1 (en) | Radiopharmaceuticals for diagnosing alzheimer's disease | |
| TWI245764B (en) | Amyloid plaque aggregation inhibitors and diagnostic imaging agents | |
| JP2025120291A (en) | Compounds for positron emission tomography | |
| Zhuang et al. | IBOX (2-(4′-dimethylaminophenyl)-6-iodobenzoxazole): a ligand for imaging amyloid plaques in the brain | |
| CA2755965C (en) | Psma-targeting compounds and uses thereof | |
| EP2170075B1 (en) | Labeled inhibitors of prostate specific membrane antigen (psma), biological evaluation, and use as imaging agents | |
| JP2024522200A (en) | Tris-linker-linked dimerized label precursors and radioactive tracers derived therefrom | |
| CA2924360A1 (en) | Labeled inhibitors of prostate specific membrane antigen (psma), their use as imaging agents and pharmaceutical agents for the treatment of prostate cancer | |
| CN103561776B (en) | Radiolabeled glutaminyl cyclase inhibitors | |
| BRPI0113470B1 (en) | COMPOSITION OF AMYLOID CONNECTION, PHARMACEUTICAL COMPOSITION AND COMPOSITION SYNTHESIS METHODS, IN VIVO DETECTION OF AMILOID DEPOSITS IN AN INDIVIDUAL AND IN HUMAN OR ANIMAL TISSUE, QUANTIFICATION OF AMILOID DEPOSIT AND DIAGNOSIS OF DENOUS TISSUE ALZHEIMER OF A NORMAL BRAIN | |
| KR20040029093A (en) | Stilbene derivatives and their use for binding and imaging amyloid plaques | |
| WO2011045415A2 (en) | New imaging agents and their use for the diagnostic in vivo of neurodegenerative diseases, notably alzheimer's disease and derivative diseases | |
| JPH11514368A (en) | Dopamine and serotonin transporter ligands and imaging agents | |
| JP2006502220A (en) | Biphenyl and fluorene as imaging agents in Alzheimer's disease | |
| JP2006514928A (en) | Compounds that can be used to diagnose and monitor diseases associated with the formation of amyloid protein fibrils | |
| EP4122500A1 (en) | Thrombus imaging radiopharmaceutical and composition | |
| WO2011095593A1 (en) | Iodo precursor for a pet imaging agent of amyloid plaques | |
| HK40048439A (en) | Novel compounds for diagnosis | |
| HK1194301A (en) | Radiolabelled glutaminyl cyclase inhibitors | |
| HK1194301B (en) | Radiolabelled glutaminyl cyclase inhibitors |